Mar 1, 2019
Principia Biopharma Presents Phase 1 Clinical Data From CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019Feb 28, 2019
Audentes Therapeutics Recognizes Rare Disease Day by Launching """"Be Bold for Courageous Patients"""" Program to Support Patients Living with Rare DiseasesFeb 28, 2019
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for AchondroplasiaFeb 28, 2019
Sierra Oncology Reports 2018 Year End ResultsFeb 27, 2019
Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate UpdateFeb 27, 2019
CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business UpdateFeb 27, 2019
Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical DataFeb 27, 2019
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial ResultsFeb 26, 2019
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2018 Financial ResultsFeb 26, 2019
ReViral Ltd Appoints Seth Hetherington as Chief Medical Officer as it Prepares its Lead RSV Candidate to Enter Pediatric Phase IIa Clinical TrialsFeb 26, 2019
Marinus Announces Leadership TransitionFeb 26, 2019
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development UpdateFeb 25, 2019
Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease PortfolioFeb 22, 2019
Kala Pharmaceuticals Reports Inducement Grand Under NASDAQ Listing Rule 5635©(4)Feb 21, 2019
ViewRay Announces FDA 510(k) Clearance for Advancements in MRI and Functional Imaging Technologies for MRIdian MRI-Guided Radiation Therapy SystemFeb 21, 2019
BELLUS Health Presents 2018 Highlights and 2019 Corporate PlanFeb 20, 2019
Constellation Pharmaceuticals Announces Appointment to Board of DirectorsFeb 20, 2019
Peloton Therapeutics Secures $150 Million in Series E FinancingFeb 19, 2019
Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018Feb 19, 2019
Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in AdultsFeb 19, 2019
Alpine Immune Sciences Presents Preclinical ALPN-101 GvHD Data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings)Feb 19, 2019
Modis Therapeutics Announces that MT1621 Receives Breakthrough Therapy Designation from FDA For the Treatment of TK2 DeficiencyFeb 13, 2019
Avedro Announces Pricing of Initial Public OfferingFeb 12, 2019
Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early PregnancyFeb 12, 2019
NeuroPace Announces New Category I CPT Code from AMA for Electrocorticography from an Implanted Brain NeurostimulatorFeb 12, 2019
Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of DirectorsFeb 11, 2019
Clementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans ProgressivaFeb 11, 2019
Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with HypoparathyroidismFeb 11, 2019
Alpine Immune Sciences Announces First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program ALPN-101Feb 11, 2019
CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®Feb 7, 2019
Health Catalyst Secures up to $100 Million with Financing Led By OrbiMedFeb 7, 2019
Alector Announces Pricing of Initial Public OfferingFeb 7, 2019
Harpoon Therapeutics Announces Pricing of Initial Public OfferingFeb 7, 2019
Sublimity Therapeutics Presents Encouraging New Efficacy Data at the 2019 Crohn's & Colitis CongressFeb 6, 2019
HLS Therapeutics Announces Graduation to the Toronto Stock ExchangeFeb 6, 2019
Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public OfferingFeb 6, 2019
Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs�CPI-444 and CPI-006 at Immuno-Oncology 360� ConferenceFeb 6, 2019
resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal ChemistryFeb 5, 2019
Aeglea BioTherapeutics Announces Proposed Public Offering of Common StockFeb 5, 2019
Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at NovartisFeb 5, 2019
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Feb 4, 2019
SI-BONE, Inc. Announces Additional Exclusive Coverage Policies for iFuseFeb 4, 2019
Avedro Launches Initial Public OfferingFeb 4, 2019
Kyn Therapeutics Appoints Douglas Carlson as Chief Financial OfficerFeb 1, 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development UpdateJan 31, 2019
Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT DesignationJan 29, 2019
scPharmaceuticals Inc. Announces Development Agreement with West Pharmaceutical Services for Next-Generation FUROSCIX� On-Body InfusorJan 28, 2019
Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical OfficerJan 28, 2019
Xenon Provides Key Regulatory Updates on XEN007 and XEN1101Jan 24, 2019
Intellia Therapeutics Names Fred Cohen, M.D., to Board of DirectorsJan 24, 2019
TELA Bio Announces First Patient in Europe Treated with OviTex® Reinforced BioScaffoldsJan 23, 2019
Selecta Biosciences Announces Pricing of Public Offering of Common StockJan 23, 2019
ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG TrialJan 22, 2019
Selecta Biosciences Announces Proposed Public Offering of Common StockJan 22, 2019
World's First MRIdian Center Celebrates Five Years of MRI-Guided Radiation TreatmentsJan 21, 2019
Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019Jan 18, 2019
Kala Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635C(4)Jan 18, 2019
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology TherapiesJan 17, 2019
Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic RetinopathyJan 17, 2019
Tricida Announces Hiring of Susannah Cantrell, Ph.D., as Chief Commercial OfficerJan 17, 2019
Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic MechanismJan 17, 2019
Terns Pharmaceuticals Announces the Appointment of Erin Quirk, M.D., as Chief Medical OfficerJan 17, 2019
Proteus Digital Health® Launches Digital Oncology Medicines to Improve Patient OutcomesJan 16, 2019
Inspire Medical Systems, Inc. Announces a Positive Coverage Policy Issued by Horizon Blue Cross Blue Shield of New JerseyJan 16, 2019
Alpine Immune Sciences Announces $25 Million Private PlacementJan 16, 2019
Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for HyperammonemiaJan 14, 2019
Inspire Medical Systems, Inc. Announces First BCBS Coverage Policy following Evidence Street’s Positive Therapy Indication SummaryJan 14, 2019
Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™Jan 14, 2019
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance TreatmentJan 10, 2019
Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell LymphomasJan 10, 2019
TELA Bio begins commercialization for Large Size OviTex® Reinforced BioScaffolds for Hernia Repair and Abdominal Wall Reconstruction after Aroa Biosurgery receives 510k clearance.Jan 9, 2019
Adimab Provides 2018 Update on Clinical PipelineJan 9, 2019
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554Jan 9, 2019
Venus Medtech Announces Agreement to Acquire Keystone Heart, LTDJan 8, 2019
Adimab Provides Year-End Update on 2018 Partnership ActivitiesJan 8, 2019
Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine AntagonistJan 8, 2019
Dr. Mary Kerr CEO NeRRe Therapeutics Presents at the Biotech Showcase, San FranciscoJan 7, 2019
Adimab Partner Innovent Receives Product Approval for PD-1 Antibody for Hodgkin's LymphomaJan 7, 2019
ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 ResultsJan 7, 2019
Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key PrioritiesJan 7, 2019
Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety ReviewsJan 7, 2019
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple ApproachesJan 7, 2019
Inspire Medical Systems, Inc. Announces a Positive Coverage Policy Issued by Horizon Blue Cross Blue Shield of New JerseyJan 7, 2019
Invitae reports 2018 preliminary financial results, delivering more than 100% volume and revenue growth in 2018; projects sustained growth in expanding markets through 2019 and beyondJan 7, 2019
SI-BONE Reports Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2018Jan 7, 2019
Cyrus Bio announces full release of rapid and accurate protein mutational free energy tool in Cyrus BenchJan 7, 2019
Gemini Therapeutics Announces the Initiation of CLARITY, a Disease Registry and Natural History Study of Subjects with Dry AMD and High-Risk GenotypesJan 7, 2019
Kala Pharmaceuticals Announces the Launch of Inveltys and the Hiring of a Specialty Ophthalmology Sales OrganizationJan 7, 2019
KaNDy Therapeutics Announces the Appointmetn of Andrew Kay as Independent Chairman of the BoardJan 7, 2019
Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel StrategyJan 7, 2019
Sublimity Therapeutics Receives Investigational New Drug (IND) Clearance from U.S. Food and Drug Administration (FDA)Jan 6, 2019
Xenon Pharmaceuticals Outlines 2019 Key MilestonesJan 4, 2019
ViewRay Announces First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial for Locally Advanced Pancreatic CancerJan 4, 2019
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Jan 4, 2019
Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™Jan 3, 2019
Selecta Biosciences Expands Potential for ImmTOR™ Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D.Jan 3, 2019
Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial OfficerJan 3, 2019
E-Scape Bio Appoints Dr. Carrolee Barlow as Chief Medical OfficerJan 3, 2019
Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead ProgramsJan 3, 2019
Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2019 CatalystsJan 3, 2019
Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554Jan 3, 2019
Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum ContagiosumJan 2, 2019
Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data From Its HPN424 Phase 1 Trial in Prostate CancerJan 2, 2019
Nora Brennan Joins TELA Bio® as Chief Financial OfficerDec 20, 2018
Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in AdultsDec 19, 2018
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635C(4)Dec 19, 2018
Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with MerckDec 19, 2018
resTORbio Appoints William Marshall, M.D., as Vice President of Medical SciencesDec 18, 2018
CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib DevelopmentDec 18, 2018
BELLUS Health Closes $35M Financing to Support Development of its Lead Drug Candidate BLU-5937 for Chronic CoughDec 17, 2018
Principia Biopharma Issues Statement About the Passing of Board Member Lewis J. ShusterDec 17, 2018
Inspire Medical Systems, Inc. Announces Full Exercise of Underwriters’ Option to Purchase Additional SharesDec 17, 2018
Turning Point Therapeutics Mourns the Death of Board Member Lewis ShusterDec 17, 2018
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPDDec 13, 2018
Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström SyndromesDec 13, 2018
CTI BioPharma Announces Restructuring PlanDec 12, 2018
Singulex receives new, broad patent for highly sensitive methods for analysis of troponinDec 12, 2018
Adaptimmune Announces that Gwen Binder will leave in January 2019Dec 12, 2018
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common StockDec 12, 2018
Synlogic Expands Capabilities in Manufacturing with the Appointment of Head of Technical Operations and Establishment of In-house Production of Clinical Trial Material for its Synthetic BioticTM MedicinesDec 11, 2018
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 DeficiencyDec 11, 2018
Anthem Blue Cross Blue Shield Joins List of 60 Commercial Plans Covering Avedro's FDA-Approved Corneal Cross-Linking ProcedureDec 11, 2018
KaNDy Therapeutics Announces Initiation of Phase 2B Trial of NT-814 For the Treatment of Troublesome Post-Menopausal SymptomsDec 11, 2018
Marinus Pharmaceuticals Announces Public Offering of Common StockDec 11, 2018
BELLUS Health Announces Pricing of $35 Million Public Offering of Common SharesDec 10, 2018
Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Dec 10, 2018
Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum DepressionDec 10, 2018
BELLUS Health Announces Overnight Marketed Equity OfferingDec 7, 2018
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Dec 7, 2018
ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial OperationsDec 6, 2018
Inspire Medical Systems, Inc. Announces Pricing of Offering of Common StockDec 6, 2018
Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell PopulationDec 6, 2018
SI-BONE, Inc. Announces Blue Cross Blue Shield of Arizona (BCBS AZ) Establishes Positive Coverage for MIS SI Joint Fusion Exclusively with the Triangular Titanium iFuse Implant SystemDec 5, 2018
ReViral Board member Raymond Schinazi decorated with French Legion of HonourDec 5, 2018
Prevail Therapeutics Announces Executive Leadership AppointmentsDec 4, 2018
Inspire Medical Systems, Inc. Announces Proposed Offering of Common StockDec 4, 2018
Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder PatientsDec 3, 2018
Selecta Biosciences Announces New Employment Inducement GrantsDec 3, 2018
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with MomelotinibDec 3, 2018
Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual MeetingDec 2, 2018
NeuroPace Announces Final Results from the Largest Prospective Clinical Study in the Field of Neuromodulation with 9-Year Follow-Up at the 2018 American Epilepsy Society Annual MeetingDec 2, 2018
Harpoon Therapeutics Presents Preclinical Data Supporting Development of HPN217, A New BCMA-Targeting TRITAC, at the 2018 American Society of Hematology (ASH) Annual MeetingNov 30, 2018
Clementia Announces the Departure of Chief Commercial OfficerNov 30, 2018
Inspire Medical Systems, Inc. Announces Publication of Data From ADHERE RegistryNov 29, 2018
Principia Biopharma Reports Positive PRN1008 Phase 2 Top-Line Results And Initiates Phase 3 Pemphigus ProgramNov 29, 2018
SI-BONE, Inc. Reports Third Quarter 2018 Financial ResultsNov 29, 2018
Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific OfficerNov 29, 2018
Realm Therapeutics Provides Update on Strategic ReviewNov 29, 2018
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737Nov 28, 2018
Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNPNov 28, 2018
Ascendis Pharma A/S Reports Third Quarter 2018 Financial ResultsNov 28, 2018
ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF OutcomesNov 28, 2018
Turning Point Therapeutics Appoints Jacob Chacko, M.D., to its Board of DirectorsNov 27, 2018
Arsanis and X4 Pharmaceuticals Agree to MergerNov 26, 2018
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)Nov 26, 2018
CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines AgencyNov 26, 2018
ORIC Pharmaceuticals Appoints Matt Panuwat as Chief Business OfficerNov 23, 2018
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635C(4)Nov 21, 2018
Rob Fuchs joins ViewRay as Chief Human Resources OfficerNov 20, 2018
Permanent J Code Issued for Avedro's Photrexa® Drug FormulationsNov 19, 2018
BELLUS Health Announces Positive Top-Line Phase 1 Results for its Chronic Cough Drug Candidate BLU-5937Nov 16, 2018
Alector Strengthens Board of Directors with Appointments of David Wehner, Richard Scheller and Louis LavigneNov 16, 2018
Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic MechanismNov 15, 2018
Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer’s DiseaseNov 15, 2018
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Alström Syndrome at ObesityWeek 2018Nov 15, 2018
Constellation Pharmaceuticals Highlights EZH2 Inhibition Program in Prostate Cancer at Biomedical ConferenceNov 15, 2018
Sierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR SymposiumNov 14, 2018
Ascendis Pharma A/S Announces Third Quarter 2018 Financial Results and Business Update Conference Call on November 28Nov 14, 2018
Attenua Announces First Patient Treated in Phase 2 Clinical Trial in Chronic Cough with BradaniclineNov 13, 2018
Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateNov 13, 2018
Modis Therapeutics Announces PRIME Designation Granted by the European Medicines Agency to MT1621 for the Treatment of TK2 DeficiencyNov 13, 2018
NextCure Raises $93 Million in Series B Financing — Proceeds Will Advance Growing Portfolio of Novel Immunomedicine Drug CandidatesNov 13, 2018
resTORbio Reports Third Quarter 2018 Financial ResultsNov 13, 2018
Sierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR SymposiumNov 13, 2018
scPharmaceuticals Inc. Reports Third Quarter 2018 Financial Results and Provides Business UpdateNov 13, 2018
Synlogic Reports Third Quarter 2018 Financial Results and Provides Program UpdatesNov 12, 2018
Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)Nov 11, 2018
Harpoon Therapeutics Announces Closing of $70M Series C FinancingNov 10, 2018
Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual MeetingNov 9, 2018
Arsanis Reports Financial Results for Third Quarter 2018Nov 9, 2018
Rhythm Pharmaceuticals Reports Third Quarter 2018 Financial ResultsNov 9, 2018
Alpine Immue Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory BoardNov 9, 2018
Harpoon Therapeutics Unveils ProTriTAC Platform: A Novel, Protease-Activated T Cell Engager Platform Designed to Access a Broad Landscape of Solid Tumor TargetsNov 9, 2018
Synthorx to Present Preclinical Data for THOR-707, a “Not-Alpha” IL-2 Synthorin, for the Treatment of Solid Tumors at SITC 2018Nov 8, 2018
Selecta Biosciences Announces Third Quarter 2018 Financial Results and Provides Corporate UpdateNov 8, 2018
ViewRay Reports Third Quarter 2018 ResultsNov 8, 2018
Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate HighlightsNov 8, 2018
Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in ChinaNov 8, 2018
Loxo Oncology Reports Third Quarter 2018 Financial ResultsNov 8, 2018
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business UpdateNov 8, 2018
Tricida Announces Third Quarter 2018 Financial ResultsNov 8, 2018
Alpine Immue Sciences Provides Corporate Update and Reports Third Quarter 2018 Financial ResultsNov 8, 2018
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2018 Financial ResultsNov 8, 2018
Kala Pharmaceuticals Reports Third Quarter 2018 Financial ResultsNov 8, 2018
resTORbio Co-Founder and Chief Medical Officer Joan Mannick, M.D., to Present on TORC1 Inhibition at The Gerontological Society of America 2018 Annual Scientific MeetingNov 8, 2018
Sierra Oncology Reports Third Quarter ResultsNov 7, 2018
Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateNov 7, 2018
Clementia Reports Third Quarter 2018 Operating Results and Pipeline UpdatesNov 7, 2018
Aerpio Reports Third Quarter 2018 Financial Results and Provides Business UpdateNov 7, 2018
Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume in Third Quarter 2018Nov 7, 2018
Waljit Dhillo, Professor in Endocrinology & Metabolism, Consultant Endocrinologist and an NIHR Research Professor at Imperial College London has joined KaNDy Therapeutics as a Scientific and Clinical AdvisorNov 7, 2018
SpringWorks Therapeutics Receives FDA Fast Track Designation for Nirogacestat for the Treatment of Adult Patients with Desmoid TumorsNov 7, 2018
Verrica Pharmaceuticals Reports Third Quarter 2018 Financial ResultsNov 6, 2018
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateNov 6, 2018
Principia Biopharma Reports Third Quarter Financial ResultsNov 6, 2018
TELA Bio® Appoints Kurt Azarbarzin to Board of DirectorsNov 6, 2018
Adaptimmune Reports Third Quarter 2018 Financial Results and Business UpdateNov 6, 2018
Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate HighlightsNov 6, 2018
resTORbio Appoints Michael Grissinger to its Board of DirectorsNov 6, 2018
Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual MeetingNov 6, 2018
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018Nov 6, 2018
Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateNov 6, 2018
ENYO Pharma announces the successful completion of phase Ib with its FXR agonist EYP001 and the start of phase II studies in two indications, NASH and HBVNov 5, 2018
Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as ChairmanNov 5, 2018
Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology MedicinesNov 5, 2018
SpringWorks Therapeutics Receives FDA Orphan Drug Designation for MEK Inhibitor (PD-0325901) for the Treatment of Neurofibromatosis Type 1Nov 1, 2018
Corvus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business UpdateNov 1, 2018
Nabriva Therapeutics Completes Submission of New Drug Application to U.S. Food and Drug Administration for Intravenous CONTEPO™ to Treat Complicated Urinary Tract InfectionsNov 1, 2018
Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of MyelofibrosisNov 1, 2018
CTI BioPharma Reports Third Quarter 2018 Financial ResultsOct 31, 2018
Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate DevelopmentsOct 31, 2018
Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance TreatmentOct 31, 2018
BELLUS Health Announces Issuance of New U.S. Patent Claiming P2X3 Selectivity as a Means of Minimizing Taste Effects for its Lead Chronic Cough Drug Candidate BLU-5937Oct 30, 2018
Cyrus Biotechnology and OpenEye Scientific Software Announce Collaboration and Cheminformatics Integration to Expedite New Drug Design and Development with Cyrus Bench PlatformOct 30, 2018
Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and CancerOct 29, 2018
ViewRay signs agreement with GenesisCare to bring the first MRIdian MRI-guided radiotherapy systems to the UKOct 29, 2018
Clementia Announces Pricing of Public Offering of Common SharesOct 29, 2018
Intellia Therapeutics Names Glenn Goddard as New Chief Financial OfficerOct 29, 2018
Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluriaOct 29, 2018
Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial ResultsOct 29, 2018
Modis Therapeutics Announces Appointment of Matthew R. Patterson to Board of DirectorsOct 26, 2018
Aeglea BioTherapeutics to Present Preclinical Data on a New Pipeline Therapeutic for Cystinuria in an Oral Presentation at the 2018 American Society of Nephrology (ASN) Annual MeetingOct 26, 2018
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis ConferenceOct 25, 2018
Pieris Pharmaceuticals Appoints Matthew L. Sherman, M.D., to its Board of DirectorsOct 25, 2018
Aerpio Pharmaceuticals Announces Presentation of Renal Function Data from TIME-2 Study of AKB-9778 in Diabetic Retinopathy Patients at American Society of Nephrology Kidney Week 2018Oct 25, 2018
Kala Pharmaceuticals Appoints Steven Zhang as Vice President of Medical AffairsOct 24, 2018
PRINCIPIA BIOPHARMA APPOINTS DOLCA THOMAS, M.D. AS CHIEF MEDICAL OFFICEROct 24, 2018
TP Therapeutics and Almac Diagnostic Services Enter into Agreement to Develop Next-Generation Sequencing Pan-Cancer Companion DiagnosticOct 23, 2018
Selecta Biosciences Presents New Interim Data from Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at ACR 2018Oct 23, 2018
Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 ResultsOct 23, 2018
NextCure Initiates Clinical Development for NC318, a Siglec-15 Targeting Antibody, for Solid TumorsOct 22, 2018
Real-Time Adaptive Radiotherapy Capabilities of ViewRay's MRIdian Highlighted at Investor & Analyst Meeting at ASTRO 2018Oct 22, 2018
Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 CongressOct 22, 2018
Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker Associated with Patient Response to CPI-444 at European Society for Medical Oncology (ESMO) 2018 CongressOct 22, 2018
Alpine Immune Sciences' Lead Program ALPN-101 Demonstrates Preclinical Activity in Inflammatory Arthritis and Neurological InflammationOct 21, 2018
Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 CongressOct 20, 2018
Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO CongressOct 19, 2018
PRINCIPIA BIOPHARMA ANNOUNCES PRN1008 RECEIVES ORPHAN-DRUG DESIGNATION FROM FDA FOR TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURAOct 19, 2018
SI-BONE Announces Closing of Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional SharesOct 19, 2018
TP Therapeutics Completes $80 Million Mezzanine Financing Co-Led by Foresite Capital and venBio PartnersOct 18, 2018
Sonendo® and TDO® Software Expand Their Strategic PartnershipOct 18, 2018
Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell TherapyOct 18, 2018
scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIXOct 17, 2018
Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 DeficiencyOct 17, 2018
Inspire Medical Systems, Inc. Announces Presentation of Clinical Efficacy Data for Inspire Therapy for Treatment of Obstructive Sleep Apnea at Annual ENT Surgeon ConferenceOct 16, 2018
PRINCIPIA ACHIEVES $10 MILLION IN ADDITIONAL MILESTONES RELATED TO DEVELOPMENT OF PRN2246/SAR442168Oct 16, 2018
KALA PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR KPI-121 0.25% FOR DRY EYE DISEASEOct 16, 2018
resTORbio Announces Additional RTB101 Phase 2b Data Demonstrating Decreased Incidence of Laboratory-Confirmed RTIs with Severe Symptoms, Total Infections and UTIsOct 15, 2018
Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid CancerOct 15, 2018
Rhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical OfficerOct 11, 2018
Otsuka and Proteus extend digital drugs tie-upOct 11, 2018
KALA PHARMACEUTICALS ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARESOct 11, 2018
Synthorx Appoints Pratik Shah, Ph.D., to its Board of DirectorsOct 10, 2018
Audentes Therapeutics Announces Pricing of Public Offering of Common StockOct 10, 2018
Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in MyelofibrosisOct 10, 2018
Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and PharmacovigilanceOct 9, 2018
ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual MeetingOct 8, 2018
Inspire Medical Systems, Inc. Announces First Implant of New Sensing Lead in EuropeOct 6, 2018
Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer from LIBRETTO-001 at the 88th Annual Meeting of the American Thyroid AssociationOct 5, 2018
Audentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle SocietyOct 4, 2018
KANDY THERAPEUTICS PRESENTS NEW COMPELLING DATA WITH LEAD CANDIDATE NT-814 AT THE NORTH AMERICAN MENOPAUSE SOCIETY 2018 ANNUAL MEETINGOct 3, 2018
Guardant Health Announces Pricing of Initial Public OfferingOct 3, 2018
Introducing the Singulex Clarity C. diff toxin A/B assay, a high-sensitivity, high-precision, single-test solution for the diagnosis of true C. difficile infectionOct 3, 2018
Audentes Therapeutics Announces Co-Founder and Chief Executive Officer Matthew R. Patterson Appointed Chairman of the Alliance for Regenerative MedicineOct 3, 2018
Corvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination StudiesOct 3, 2018
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)Oct 2, 2018
Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy VolunteersOct 2, 2018
Venus Medtech Announces Agreement to Acquire Keystone Heart, LTDOct 2, 2018
KALA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCKOct 2, 2018
KALA PHARMACEUTICALS ANNOUNCES FINANCING FROM ATHYRIUM CAPITAL MANAGEMENT TOTALING $110 MILLIONOct 2, 2018
Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive OfficerOct 1, 2018
FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 DeficiencyOct 1, 2018
CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data ReviewOct 1, 2018
MODIS THERAPEUTICS ANNOUNCES $30M SERIES A FINANCINGSep 28, 2018
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated painSep 28, 2018
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE MeetingSep 28, 2018
Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of ObesitySep 27, 2018
Selecta Biosciences Appoints Carsten Brunn, Ph.D. as President and Chief Executive OfficerSep 26, 2018
Clementia Announces Updated Phase 2 Part B Data on Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP)Sep 26, 2018
Arvinas Announces Pricing of Initial Public OfferingSep 26, 2018
Genewiz To Be Acquired By Brooks AutomationSep 25, 2018
Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer from LIBRETTO-001 at the IASLC 19th World Conference on Lung CancerSep 25, 2018
Cigna Is Newest Payer to Join Growing List of Commercial Plans Covering Avedro’s FDA-Approved Cross-Linking Procedure—133 Million Lives Covered in TotalSep 25, 2018
Avedro Names Tim Homer Vice President of Health Policy & Market Access in Continued Effort to Expand Market Access and Reimbursement of Cross-LinkingSep 25, 2018
Marinus Completes Enrollment in its Magnolia Postpartum Depression StudySep 25, 2018
BELLUS Health Announces Appointment of Clinical Advisory BoardSep 24, 2018
TP Therapeutics Announces Updated Interim Phase 1/2 Clinical Trial Data of Repotrectinib (TPX-0005) in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer Patients at 19th World Conference on Lung CancerSep 24, 2018
OncLive report on Repotrectinib: “Repotrectinib Shows Promising Activity in ROS1+ NSCLC”Sep 24, 2018
Verrica Pharmaceuticals Inc. Announces Inclusion in Russell 2000® and Russell 3000® IndexesSep 24, 2018
HLS Therapeutics Announces that Amarin's REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary EndpointSep 20, 2018
SI-BONE Files Registration Statement for Proposed Initial Public OfferingSep 20, 2018
Issue of Shares & PDMR AnnouncementSep 19, 2018
Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal DementiaSep 19, 2018
Silverback Therapeutics Extends Series A to $47.5 Million to Advance Pipeline of First-in-Class Systemically Delivered, Locally Active TherapiesSep 18, 2018
Principia Biopharma Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters’ Option to Purchase Additional SharesSep 18, 2018
Sonendo Ships a Record 100,000 GentleWave Procedure InstrumentsSep 18, 2018
resTORbio Appoints Meredith Manning as Chief Commercial OfficerSep 17, 2018
ORIC Pharmaceuticals appoints Pratik Multani, MD, as Chief Medical OfficerSep 17, 2018
Realm Therapeutics Provides Corporate Update and Hires Advisor to Support Strategic Review including Formal Sale ProcessSep 17, 2018
Xenon Pharmaceuticals Announces Closing of its $63.0 Million Public Offering of Common SharesSep 17, 2018
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018Sep 13, 2018
Acibadem Maslak Hospital in Turkey Introduces Next Generation Cancer Care with MRIdian MR-Image Guided Radiation TherapySep 13, 2018
Principia Biopharma Announces Pricing Of Initial Public OfferingSep 12, 2018
Constellation Pharmaceuticals Congratulates Dr. David Allis and Dr. Michael Grunstein, Winners of the 2018 Lasker AwardSep 12, 2018
Verrica Announces Successful Phase 2 Innovate Trial and Complete Enrollment of Phase 3 Trials of VP-102 in Molluscum Contagiosum Ahead of ScheduleSep 12, 2018
Xenon Pharmaceuticals Announces Pricing of $63.0 Million Public Offering of Common SharesSep 11, 2018
TELA Bio Announces Publication of Case Series Evaluating OviTex Reinforced BioScaffolds in Hiatal and Inguinal Hernia RepairSep 11, 2018
Invitae Appoints Chitra Nayak to its Board of DirectorsSep 10, 2018
Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. To Its Board Of DirectorsSep 10, 2018
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing TechnologySep 10, 2018
Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 ProgramSep 7, 2018
Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary SharesSep 6, 2018
BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid TumorsSep 6, 2018
Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory JournalSep 6, 2018
Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of EpilepsySep 5, 2018
Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary SharesSep 5, 2018
Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292Sep 5, 2018
Marinus Appoints Scott Braunstein, MD to its Board of DirectorsSep 5, 2018
SpringWorks Therapeutics Announces Appointment of Saqib Islam as Chief Executive OfficerSep 4, 2018
Pieris Pharmaceuticals Announces Dosing Of First Patient In Phase I Combination Trial For Prs-343 Plus Anti-Pd-L1 ImmunotherapySep 4, 2018
Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 DeficiencySep 4, 2018
Constellation Pharmaceuticals Announces Appointments to Board of DirectorsSep 4, 2018
Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)Aug 30, 2018
Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate UpdateAug 29, 2018
Ascendis Pharma A/S Reports Second Quarter 2018 Financial ResultsAug 29, 2018
Kandy Therapeutics Successfully Raises £25 million in a Series C Financing Funding to Advance a Breakthrough Non-hormonal Treatment for Symptoms of the Menopause, Into a Phase 2b Study in Q4 2018Aug 29, 2018
Xenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS StudyAug 27, 2018
Loxo Oncology Announces Submission of European Marketing Authorization Application for LarotrectinibAug 23, 2018
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith as President and Chief Executive OfficerAug 23, 2018
Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas RevolutionAug 23, 2018
Kala Pharmaceuticals Announces FDA Approval of Inveltys for the Treatment of Post-operative Inflammation and Pain Following Ocular SurgeryAug 22, 2018
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead SciencesAug 22, 2018
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance MomelotinibAug 21, 2018
Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular MyopathyAug 20, 2018
Xtant Medical Announces Appointment of Chief Financial OfficerAug 17, 2018
ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common StockAug 16, 2018
Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOPAug 16, 2018
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical OfficerAug 15, 2018
Sonendo® Announces GentleWave® System Integration With TDO® Endodontic SoftwareAug 15, 2018
Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose CohortAug 15, 2018
resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of DirectorsAug 15, 2018
Verrica Appoints Neetu Dhaliwal as Vice President of Business DevelopmentAug 14, 2018
Aerpio Reports Second Quarter 2018 Financial Results and Provides Business UpdateAug 14, 2018
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2018 Financial ResultsAug 14, 2018
Realm Therapeutics Reports Top-line Data from Phase 2 Trial of PR022 in Atopic Dermatitis and First Half 2018 Financial ResultsAug 14, 2018
scPharmaceuticals Inc. Reports Second Quarter 2018 Financial Results and Provides Business UpdateAug 13, 2018
Arsanis Reports Financial Results for Second Quarter 2018Aug 13, 2018
Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for PhenylketonuriaAug 9, 2018
Pieris Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate UpdateAug 9, 2018
Clementia Reports Second Quarter 2018 Operating Results and Pipeline UpdatesAug 9, 2018
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial ResultsAug 9, 2018
Loxo Oncology Reports Second Quarter 2018 Financial ResultsAug 9, 2018
Nabriva Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate HighlightsAug 9, 2018
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2018 Financial ResultsAug 9, 2018
Kala Pharmaceuticals Reports Second Quarter 2018 Financial ResultsAug 9, 2018
resTORbio Reports Second Quarter 2018 Financial ResultsAug 9, 2018
Sierra Oncology Reports Second Quarter ResultsAug 8, 2018
Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate UpdateAug 8, 2018
Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontotemporal DementiaAug 8, 2018
ObsEva reports Second Quarter 2018 Financial Results and Provides Business UpdateAug 8, 2018
Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial ResultsAug 8, 2018
Tricida Announces Second Quarter 2018 Financial Results and Provides Update on Key InitiativesAug 8, 2018
Cyrus Biotechnology Appoints Jake Litwicki as VP of EngineeringAug 8, 2018
Synlogic Reports Second Quarter 2018 Financial Results and Provides Program UpdatesAug 7, 2018
Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular MyopathyAug 7, 2018
Inspire Medical Systems, Inc. Announces Second Quarter 2018 Financial ResultsAug 7, 2018
Invitae Reports More than 160% Annual Revenue Growth Driven by Nearly 140% Annual Growth in Volume in Second Quarter 2018Aug 7, 2018
SI-BONE, Inc. Announces 23 Commercial Health Insurance Plans Now “Exclusively” Cover Triangular iFuse Implant System® Based on Published Clinical EvidenceAug 7, 2018
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018Aug 7, 2018
Verrica Reports Second Quarter 2018 Financial ResultsAug 7, 2018
Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate UpdateAug 6, 2018
Alpine Immune Sciences Strengthens Leadership Team with Appointment of Mark Litton as President and Chief Operating OfficerAug 6, 2018
OmniGuide, Inc. to Acquire Lisa Laser, Developer of Surgical Laser ProductsAug 3, 2018
ViewRay Reports Second Quarter 2018 Financial ResultsAug 2, 2018
Adaptimmune Reports Second Quarter 2018 Financial Results and Business UpdateAug 2, 2018
CTI BioPharma Reports Second Quarter 2018 Financial ResultsAug 2, 2018
Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial ResultsAug 2, 2018
Corvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business UpdateAug 1, 2018
Intellia Therapeutics Announces Second Quarter 2018 Financial ResultsAug 1, 2018
ReViral announces US$55 million series B fundraising to advance RSV clinical studiesAug 1, 2018
Tricida Announces Hiring of Dawn Parsell as Senior Vice President of Clinical DevelopmentAug 1, 2018
Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance TreatmentJul 31, 2018
Thomas W. Burns, CEO of Glaukos, Joins Avedro's Board of DirectorsJul 31, 2018
Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye DiseaseJul 26, 2018
Principia Confirms Human CNS Exposure and Good Tolerability of Oral BTK Inhibitor PRN2246Jul 26, 2018
Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $50 MillionJul 25, 2018
Alector Announces $133 Million in Series E Financing to Advance Broad Portfolio of Immuno-Neurology and Immuno-Oncology ProgramsJul 25, 2018
ObsEva Expands Executive Team Hiring a Chief Commercial OfficerJul 25, 2018
resTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101Jul 24, 2018
ViewRay Appoints Scott Drake as President, Chief Executive Officer and a Member of the Board of Directors, Shar Matin as Chief Operating Officer, and D. Keith Grossman as a Member of the Board of DirectorsJul 24, 2018
GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSKJul 24, 2018
Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante TherapeuticsJul 24, 2018
scPharmaceuticals Announces Appointment of Two New DirectorJul 23, 2018
Ascendis Pharma A/S Announces Poster Presentation on TransCon Technology at the Controlled Release Society Annual MeetingJul 23, 2018
Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of ObesityJul 20, 2018
Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Venture CapitalJul 20, 2018
Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesJul 19, 2018
Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive OfficerJul 18, 2018
Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing CohortsJul 18, 2018
Constellation Pharmaceuticals Announces Pricing of Initial Public OfferingJul 18, 2018
CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDAJul 16, 2018
Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of DirectorsJul 13, 2018
Clementia Appoints Experienced Financial Executive Steve Forte as Chief Financial OfficerJul 12, 2018
Xenon Pharmaceuticals Announces At-The-Market Equity OfferingJul 12, 2018
Synthorx Expands Leadership Team with Three Key HiresJul 11, 2018
resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune Function and Decreased Infection Rates in People Aged 65 Years and OlderJul 10, 2018
Cyrus Biotechnology Launches Immune Epitope Prediction SoftwareJul 10, 2018
Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic DermatitisJul 9, 2018
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin LymphomaJul 5, 2018
Clementia Appoints Industry Executive Shawn Tomasello to its Board of DirectorsJul 4, 2018
Realm Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approves Listing of ADSs Representing Ordinary SharesJul 2, 2018
Tricida Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesJul 2, 2018
CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with RuxolitinibJun 28, 2018
Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100Jun 28, 2018
Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, ImmunotherapyJun 28, 2018
scPharmaceuticals Appoints Frederick Hudson to Board of DirectorsJun 27, 2018
Adicet Bio appoints Stewart Abbot, Ph.D. as Chief Scientific OfficerJun 27, 2018
Inspire Medical Systems, Inc. Announces Regulatory Approval of Inspire Therapy for Treatment of Moderate to Severe Obstructive Sleep Apnea in JapanJun 26, 2018
Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45.0 Million Public Offering of Common StockJun 25, 2018
Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel DiseaseJun 25, 2018
Aerpio Pharmaceuticals Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital MarketJun 25, 2018
Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier ScreeningJun 25, 2018
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesJun 25, 2018
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018Jun 22, 2018
Lilly Completes Acquisition of ARMO BioSciencesJun 21, 2018
University of Wisconsin Begins Patient Treatments with ViewRay's MRIdian LinacJun 21, 2018
Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and AcromegalyJun 21, 2018
Kandy Therapeutics and Nerre Therapeutics Announce the Appointment of Jo Craig as Head of Chemistry Manufacturing and ControlsJun 21, 2018
KaNDy Therapeutics and NeRRe Therapeutics announce the appointment of Jo Craig as Head of Chemistry Manufacturing and ControlsJun 21, 2018
Natera Develops Powerful Kidney Transplant Rejection BiomarkerJun 20, 2018
ObsEva Announces Pricing of Follow-on Public OfferingJun 19, 2018
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome EditingJun 19, 2018
Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development PlanJun 19, 2018
Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency DisorderJun 19, 2018
Verrica Pharmaceuticals Inc. Announces Closing of Initial Public OfferingJun 18, 2018
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with EndometriosisJun 18, 2018
Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of ObesityJun 18, 2018
Crinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical OfficerJun 18, 2018
Avedro Announces Enrollment of First Patient in U.S. Pivotal Phase 3 Epi-on Corneal Cross-Linking Trial for Progressive KeratoconusJun 15, 2018
Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018Jun 14, 2018
Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 ProgramJun 14, 2018
Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of ObesityJun 13, 2018
Pioneer of MR Image-Guided Radiotherapy, Washington University, Begins First Clinical Treatments with its Second ViewRay MRIdian SystemJun 13, 2018
Invitae Study of 143,000 Patients Shows Importance of Routinely Including Deletion and Duplication Detection with Sequencing in Genetic TestingJun 13, 2018
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease WeekJun 12, 2018
E-Scape Bio Obtains Worldwide Rights from AbbVie for Selective S1P5 Program Targeting CNS-related Lysosomal Storage DisordersJun 12, 2018
resTORbio Announces Appointment of Kerry Russell, M.D., Ph.D., as Vice President of Clinical DevelopmentJun 11, 2018
Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self?renewing, and Capable of Persistent Anti-Tumor EffectsJun 11, 2018
Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of PhenylketonuriaJun 7, 2018
Inspire Medical Systems, Inc. Reports First Quarter 2018 Financial ResultsJun 7, 2018
Kandy Therapeutics Announces Positive Clinical Data with Lead Candidate Nt-814 for the Treatment of Symptoms of the MenopauseJun 6, 2018
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for HypoparathyroidismJun 5, 2018
Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular MyopathyJun 5, 2018
Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients with Metabolic AcidosisJun 4, 2018
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cellsJun 4, 2018
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCOJun 4, 2018
Tricida Announces Kathryn Falberg Joins Board of DirectorsJun 4, 2018
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease WeekJun 4, 2018
TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 StudyJun 2, 2018
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk ProfileJun 2, 2018
Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual MeetingJun 1, 2018
ObsEva SA to Seek SIX Share ListingJun 1, 2018
NeuroPace Launches Next Generation RNS System, the World’s Only Brain-Computer Interface for the Treatment of Refractory EpilepsyMay 31, 2018
Nabriva Therapeutics to Present Lefamulin Data at ASM MicrobeMay 31, 2018
scPharmaceuticals Receives Complete Response Letter from the FDA for FUROSCIX®May 30, 2018
Ascendis Pharma A/S Reports First Quarter 2018 Financial ResultsMay 29, 2018
FDA Accepts Larotrectinib New Drug Application and Grants Priority ReviewMay 24, 2018
Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic DermatitisMay 23, 2018
World-Leading Oncologists to Meet in Miami for Adaptive MR Image-Guided Radiotherapy SymposiumMay 23, 2018
Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOPMay 23, 2018
Realm Therapeutics Publicly Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary SharesMay 22, 2018
OmniGuide Surgical Announces Commercial Launch of C-LAS Line of Sight CO2 Laser SystemMay 22, 2018
resTORbio to Host Key Opinion Leader Symposium on TORC1 InhibitionMay 21, 2018
Xtant Medical Receives FDA 510(K) Clearance for InTice™-C Porous Titanium Cervical Interbody SystemMay 21, 2018
Cerapedics Announces Results From IVANOS Study of i-FACTOR Peptide Enhanced Bone GraftMay 21, 2018
Nabriva Therapeutics Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-Acquired Bacterial PneumoniaMay 21, 2018
Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPDMay 17, 2018
Pharming Group Interim Report on Financial Results for the First Quarter 2018May 17, 2018
Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Society of Gene and Cell Therapy 21st Annual MeetingMay 17, 2018
TP Therapeutics Announces Phase 1 Data of Ropotrectinib (TPX-0005) to be Presented at the Annual American Society of Clinical Oncology MeetingMay 16, 2018
Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular MyopathyMay 16, 2018
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual MeetingMay 16, 2018
Loxo Oncology Announces Details of LOXO-292 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingMay 16, 2018
ObsEva Reports First Quarter 2018 Financial Results and Provides Business UpdateMay 15, 2018
Synlogic Reports First Quarter 2018 Financial Results and Provides Business UpdateMay 15, 2018
Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat ConferenceMay 15, 2018
Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat ConferenceMay 14, 2018
Rhythm Pharmaceuticals Reports First Quarter 2018 Financial ResultsMay 14, 2018
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial ResultsMay 10, 2018
Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results And Provides Corporate UpdateMay 10, 2018
ViewRay Reports First Quarter 2018 Financial ResultsMay 10, 2018
Lilly Announces Agreement To Acquire ARMO BioSciencesMay 10, 2018
Arsanis Reports Business Highlights and Financial Results for First Quarter 2018May 10, 2018
Kala Pharmaceuticals Reports First Quarter 2018 Financial ResultsMay 10, 2018
resTORbio Reports First Quarter 2018 Financial ResultsMay 10, 2018
Sierra Oncology Reports First Quarter ResultsMay 10, 2018
Synlogic Announces Leadership ChangeMay 9, 2018
Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate UpdateMay 9, 2018
Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate UpdateMay 9, 2018
Clementia Reports First Quarter 2018 Operating Results and Pipeline UpdatesMay 9, 2018
Adaptimmune Reports First Quarter 2018 Financial Results and Business UpdateMay 9, 2018
Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018May 9, 2018
Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency ObesityMay 9, 2018
Kala Pharmaceuticals Strengthens Commercial Organization In Preparation For First Product LaunchMay 9, 2018
resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the ElderlyMay 8, 2018
Natera Reports First Quarter 2018 Financial ResultsMay 8, 2018
First Cardiac Procedure Using the AcQMap® System by Acutus Medical® Successfully Performed in the United StatesMay 8, 2018
Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating OfficerMay 8, 2018
Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial ResultMay 8, 2018
Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNPMay 8, 2018
Loxo Oncology Reports First Quarter 2018 Financial ResultsMay 8, 2018
Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate HighlightsMay 8, 2018
Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate UpdateMay 7, 2018
Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of EndocrinologyMay 7, 2018
Inspire Medical Systems, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 7, 2018
Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular DystrophyMay 7, 2018
ORIC has appointed Jacob Chacko, MD as Chief Executive OfficerMay 7, 2018
scPharmaceuticals Inc. Reports First Quarter 2018 Financial Results and Provides Business UpdateMay 3, 2018
Stereotaxis and Acutus Medical Announce Strategic CollaborationMay 3, 2018
Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business UpdateMay 3, 2018
CTI BioPharma Reports First Quarter 2018 Financial ResultsMay 2, 2018
Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial GrowthMay 2, 2018
Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial ResultsMay 2, 2018
Final Results for the Year Ended December 31, 2017 and Business UpdateMay 1, 2018
Intellia Therapeutics Announces First Quarter 2018 Financial ResultsApr 30, 2018
Miami Cancer Institute at Baptist Health South Florida Becomes Second Institution in the United States to Treat Patients with ViewRay’s MRIdian® LinacApr 30, 2018
Adicet Bio Appoints Elizabeth “E.J.” Read, M.D. as its Chief Technology OfficerApr 30, 2018
Attenua Raises $35M in Series A Financing to Advance Therapy for Chronic CoughApr 30, 2018
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ CytokinesApr 30, 2018
Adicet Bio Appoints Elizabeth “E.J.” Read, M.D. as its Chief Technology OfficerApr 27, 2018
Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial GrowthApr 27, 2018
Invitae Announces New Program to Offer Genetic Testing to Aid Diagnosis of Spinal Muscular Atrophy (SMA)Apr 26, 2018
Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced CancerApr 25, 2018
Pieris Pharmaceuticals Appoints Ann Barbier, M.D., Ph.D., To Its Board Of DirectorsApr 25, 2018
ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingApr 24, 2018
Singulex Clarity C. diff toxins A/B assay in development shown to be ultrasensitive and highly specific compared with currently available testing optionsApr 24, 2018
Sonendo Ships 50,000 GentleWave Procedure Instruments to EndodontistsApr 23, 2018
Inspire Medical Systems, Inc. Announces Commencement of its Initial Public OfferingApr 23, 2018
Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st Annual MeetingApr 23, 2018
ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)Apr 23, 2018
Graybug Vision Announces Presentations on Novel Treatments for Wet AMD and Glaucoma at ARVO 2018 Annual MeetingApr 20, 2018
Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple OsteochondromasApr 19, 2018
VU University Medical Center in Amsterdam Delivers First Ever Linear Accelerator-Based On-Table Adaptive MR Image-Guided Radiotherapy Treatment on ViewRay MRIdian LinacApr 19, 2018
Cyrus Biotechnology Exhibits at the PEGS Protein Engineering Summit in Boston, April 30th May 3rdApr 18, 2018
ViewRay Unveils New Soft Tissue Visualization Technologies to Further Advance MR Image-Guided RadiotherapyApr 18, 2018
Aeglea BioTherapeutics Prices Public Offering of Common StockApr 18, 2018
Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of PhenylketonuriaApr 17, 2018
Aeglea BioTherapeutics Announces Proposed Public Offering of Common StockApr 17, 2018
Alpine Immune Sciences Announces Preclinical Data Demonstrating ALPN-202 Eliminates Tumors and Creates Persistent Tumor Resistance in a Murine Cancer ModelApr 17, 2018
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual MeetingApr 16, 2018
TELA Bio Announces Series B Investment by Checkmate CapitalApr 16, 2018
Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual MeetingApr 16, 2018
Summary ToggleSynlogic Presents Preclinical Data from Synthetic Biotic Immuno-Oncology Program at the American Association for Cancer Research 2018 Annual MeetingApr 13, 2018
Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial PneumoniaApr 12, 2018
Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics MeetingApr 10, 2018
Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testingApr 10, 2018
Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion DiagnosticsApr 10, 2018
Avedro Names James Schuermann Chief Business OfficerApr 9, 2018
SI-BONE, Inc. Announces Publication of 3-Year Long-term Prospective Outcomes Including Randomized Controlled Trial Data on 103 Patients Post SI Joint Fusion with Triangular iFuse Implant SystemApr 9, 2018
SI-BONE, Inc. Hosts ISASS 2018 Sacroiliac Joint Workshop led by David Polly, MD, Bengt Sturesson, MD, Peter Whang, MD and Brad Duhon, MDApr 9, 2018
Constellation Pharmaceuticals Announces $100 Million FinancingApr 9, 2018
Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRSApr 6, 2018
Inspire Medical Systems, Inc. Announces Filing of Registration Statement for Proposed Initial Public OfferingApr 6, 2018
Summary ToggleSynlogic Announces Registered Direct Offering of Common StockApr 5, 2018
Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual MeetingApr 4, 2018
University Clinic Heidelberg Completes Installation and Commissioning of ViewRay's MRIdian MR Image-Guided Radiotherapy LinacApr 4, 2018
Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual MeetingApr 4, 2018
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation PlatformApr 4, 2018
NextCure Appoints Kevin N. Heller, M.D., as Chief Medical Officer and Steve Cobourn, CPA, as Chief Financial Officer.Apr 2, 2018
Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA (Pembrolizumab) Combination TrialsApr 2, 2018
Ascendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial OfficerApr 2, 2018
Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi SyndromeApr 2, 2018
Synlogic Doses First Patient in Phase 1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with CirrhosisMar 29, 2018
HLS Therapeutics Announces Fiscal 2017 Financial ResultsMar 29, 2018
resTORbio Reports Fourth Quarter and Full Year 2017 Financial ResultsMar 28, 2018
Ascendis Pharma A/S Reports Full Year 2017 Financial ResultsMar 28, 2018
Invitae Announces Pricing of Public Offering of Common StockMar 28, 2018
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2017 Financial ResultsMar 28, 2018
Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.Mar 27, 2018
ViewRay Surpasses 50th Order for MRIdian System for Precision Cancer TreatmentMar 27, 2018
Nabriva Therapeutics and Roivant Sciences Enter into License Agreement to Develop and Commercialize Lefamulin in Greater ChinaMar 26, 2018
TELA Bio Announces Investment Agreement with ProMedica Innovations Venture FundMar 26, 2018
Invitae Announces Proposed Public Offering of Common StockMar 26, 2018
Loxo Oncology Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion CancerMar 26, 2018
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ResultsMar 23, 2018
Invitae expands network of patients in rare and ultra-rare diseasesMar 21, 2018
Study shows cardiac troponin measurement using ultra-sensitive Singulex cTnI test can identify the presence and severity of coronary artery disease in stable, symptomatic outpatientsMar 21, 2018
Nabriva Therapeutics Appoints Jennifer Schranz, M.D., as Chief Medical OfficerMar 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board MemberMar 20, 2018
ReViral to present at American Chemical SocietyMar 20, 2018
scPharmaceuticals Inc. Reports Fourth Quarter 2017 Financial ResultsMar 20, 2018
Synlogic Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateMar 19, 2018
Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018Mar 19, 2018
PMV Pharma Appoints Salim Yazji, M.D. as Chief Medical OfficerMar 19, 2018
Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018Mar 19, 2018
resTORbio Announces Formation of Clinical Advisory BoardMar 19, 2018
Synlogic to Present Data at the American Association for Cancer Research 2018 Annual MeetingMar 16, 2018
Nearly 200 Oncology Experts Gather to Discuss Advanced Applications of MR Image-Guided RadiotherapyMar 16, 2018
Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business Update Conference Call on March 28Mar 16, 2018
Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic informationMar 16, 2018
Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate HighlightsMar 16, 2018
HLS Therapeutics Inc. Opens the MarketMar 15, 2018
ViewRay's MRIdian MR Image-Guided Radiotherapy Linac Receives Japanese Regulatory Approval (Shonin)Mar 15, 2018
Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business UpdateMar 15, 2018
Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cellsMar 14, 2018
Cerapedics Receives FDA IDE Approval to Initiate Study of P-15L Bone Graft for Transforaminal Lumbar Interbody Fusion SurgeryMar 14, 2018
ViewRay Finalizes Order for MR Image-Guided Radiation Therapy System at University Hospital ZurichMar 14, 2018
Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin AntibodiesMar 14, 2018
Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial ResultsMar 14, 2018
Alpine Immune Sciences Announces Poster Presentation at the 2018 AACR Annual MeetingMar 14, 2018
Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual MeetingMar 14, 2018
HLS Therapeutics Completes Merger with Automodular CorporationMar 13, 2018
Study adds to understanding about utility of ultra-sensitive cardiac troponin measurement in diagnosing and predicting cardiovascular syndromesMar 13, 2018
Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial ResultsMar 13, 2018
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateMar 13, 2018
Crinetics Pharmaceuticals Completes $63.5 Million Series B FinancingMar 13, 2018
Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical OfficerMar 13, 2018
Natera Reports Fourth Quarter and Fiscal Year 2017 Financial ResultsMar 12, 2018
ViewRay Reports Fourth Quarter and Full Year 2017 Financial ResultsMar 12, 2018
Corvus Pharmaceuticals Announces Closing of Public Offering of Common StockMar 12, 2018
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ResultsMar 12, 2018
Realm Therapeutics Provides Clinical Update, including Results from a Phase 2 Study of PR013 in Allergic ConjunctivitisMar 12, 2018
Synlogic Presents Clinical and Preclinical Data from Synthetic Biotic™ Medicine Programs for Treatment of Inborn Errors of Metabolism at Annual Meeting of The Society for Inherited Metabolic DisordersMar 9, 2018
Pieris Pharmaceuticals Reports Full-Year 2017 Financial Results And Corporate UpdateMar 9, 2018
Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017Mar 9, 2018
ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business UpdateMar 9, 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA OncologyMar 8, 2018
Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate UpdateMar 8, 2018
Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with PegzilarginaseMar 8, 2018
Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with Parkinson's and Other Neurodegenerative DiseasesMar 7, 2018
TigerConnect Teams with QGendaMar 7, 2018
CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial ResultsMar 7, 2018
Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate UpdateMar 7, 2018
Pharming Group Report on Preliminary Financial Results for 2017Mar 6, 2018
Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic DisordersMar 6, 2018
TigerText Renames As TigerConnect to Welcome a New Era of Clinical CommunicationMar 6, 2018
Marinus Pharmaceuticals Provides Business Update and 2017 Financial ResultsMar 5, 2018
Kala Pharmaceuticals Appoints Gregory Perry To Board Of Directors And As Audit Committee ChairMar 2, 2018
Tricida Announces $100 Million Venture Debt Financing From Hercules CapitalMar 2, 2018
Sierra Oncology Announces Pricing of Public Offering of Common StockMar 2, 2018
Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis PatientsMar 1, 2018
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateMar 1, 2018
Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial ResultsMar 1, 2018
ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual MeetingFeb 28, 2018
Study shows high-sensitivity cardiac troponin I concentrations is an independent predictor of obstructive coronary artery disease in patients with suspected stable anginaFeb 28, 2018
Clementia Reports 2017 Operating Results and Business HighlightsFeb 28, 2018
Aerpio Pharmaceuticals Presents Analysis from TIME-2 Study Regarding Effects of AKB-9778 on Renal Function at 2018 Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ InjuryFeb 27, 2018
Invitae expands existing credit facility to provide up to $40.0 million in available growth capitalFeb 27, 2018
Sierra Oncology Reports 2017 Year End ResultsFeb 27, 2018
Verona Pharma Reports Operational Update and Financial Results for Full Year Ended December 31, 2017Feb 26, 2018
ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVFFeb 21, 2018
Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of MedicineFeb 21, 2018
Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual MeetingFeb 20, 2018
Ascendis Pharma A/S Announces Proposed Public Offering of ADSsFeb 20, 2018
Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical TrialFeb 16, 2018
Pieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional SharesFeb 15, 2018
Realm Therapeutics Highlights Strong 2017 Performance and Outlines 2018 MilestonesFeb 14, 2018
Pieris Pharmaceuticals Announces Pricing of its Public OfferingFeb 14, 2018
Xtant Medical Announces Exchange of Outstanding Convertible Notes and Closing of Private PlacementFeb 13, 2018
Pieris Pharmaceuticals Announces Public Offering of Common StockFeb 13, 2018
CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common StockFeb 13, 2018
Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity Following Administration of Novel STING Agonist-producing Synthetic Biotic� MedicineFeb 13, 2018
Verona Pharma Provides Clinical Development UpdateFeb 12, 2018
Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar SyndromeFeb 12, 2018
Invitae reports over 150% volume and over 170% revenue growth for 2017Feb 10, 2018
Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma ForumFeb 9, 2018
Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology CollaborationFeb 9, 2018
Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic RetinopathyFeb 9, 2018
Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC® ARV-110 at ASCO 2018 Genitourinary Cancers SymposiumFeb 9, 2018
CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common StockFeb 8, 2018
Glaukos iStent® Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medication Burden in Patients with Severe Glaucoma, According to New StudyFeb 6, 2018
Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease ProgramFeb 6, 2018
Sierra Oncology to host Program Update in New York on February 27thFeb 5, 2018
Positive results achieved in ReViral’s Phase IIa RSV challenge studyFeb 5, 2018
CTI BioPharma Announces Launch of Follow-On OfferingJan 31, 2018
Clementia Appoints Industry Veteran Pierre Legault to its Board of DirectorsJan 31, 2018
Summary ToggleSynlogic Announces Underwriters’ Option Exercise in FullJan 30, 2018
resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesJan 29, 2018
Audentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesJan 29, 2018
Sierra Oncology to Present at the DNA Damage Response Therapeutics SummitJan 25, 2018
ARMO BioSciences Announces Pricing of Initial Public OfferingJan 25, 2018
CTI BioPharma Provides Corporate and European Regulatory UpdateJan 25, 2018
resTORbio Announces Pricing of Initial Public OfferingJan 24, 2018
Audentes Therapeutics Announces Pricing of Public Offering of Common StockJan 24, 2018
Synlogic Announces Pricing of Public Offering of Common StockJan 18, 2018
Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism ConferenceJan 18, 2018
CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOXJan 17, 2018
Pharming Announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST® for Prophylaxis of Hereditary Angioedema AttacksJan 11, 2018
Adimab Initiates Update on Clinical Progression of Partner ProgramsJan 10, 2018
Adimab Announces Antibody Discovery Collaboration with Boehringer IngelheimJan 10, 2018
Glaukos Corporation’s iDose™ Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile in 12-Month Interim CohortJan 8, 2018
Adimab Provides Year-End Update on 2017 Partnership ActivitiesJan 8, 2018
ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2017 ResultsJan 8, 2018
Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell DoseJan 8, 2018
Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy CompanyJan 8, 2018
Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTHJan 8, 2018
Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018Jan 8, 2018
Tricida Announces Hiring of Jeroen van Beek, Ph.D., as Chief Commercial Officer and Senior Vice PresidentJan 8, 2018
Xenon Pharmaceuticals Outlines Key Milestones for 2018Jan 6, 2018
Cleave Biosciences Promotes Kanya Rajangam to Chief Medical OfficerJan 5, 2018
Kala Pharmaceuticals Announces Topline Results For Two Phase 3 Trials (Stride 1 And Stride 2) Of Kpi-121 0.25% In Dry Eye DiseaseJan 5, 2018
Kala Pharmaceuticals Announces New Drug Application For Inveltys™ (Kpi-121 1%) Has Been Accepted For Review By The U.S. Food And Drug AdministrationJan 4, 2018
Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular MyopathyJan 4, 2018
Paul Stead Joins Adaptimmune as Vice President of Business DevelopmentJan 4, 2018
Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of ObesityJan 4, 2018
Arvinas Announces Research Collaboration and License Agreement with Pfizer Inc. for the Discovery and Development of Protein Degradation Drug CandidatesJan 4, 2018
Neurogastrx, Inc. Raises $45M Series A To Bring Lead Gi Candidate Through Proof Of ConceptJan 3, 2018
Glaukos Submits IDE Application to FDA to Study iStent infinite™ Trabecular Micro-Bypass SystemJan 3, 2018
Ascendis Pharma Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone for Pediatric Growth Hormone DeficiencyJan 3, 2018
ResTORbio Appoints Lynne Sullivan To Its Board Of DirectorsJan 2, 2018
SI-BONE, Inc. Announces Blue Cross Blue Shield Association Raises Clinical Evidence Rating for MIS SI Joint FusionDec 22, 2017
Dental Partners and Spring & Sprout Select TigerText to Bring Secure Communications to Its Dental Practices NationwideDec 21, 2017
Automodular Corporation Agrees to a Business Combination with HLS Therapeutics Inc.Dec 21, 2017
SONENDO® APPOINTS MICHAEL WATTS AS CHIEF FINANCIAL OFFICERDec 20, 2017
Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion CancersDec 18, 2017
Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive OfficerDec 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism PathwaysDec 13, 2017
PRINCIPIA BIOPHARMA INITIATES CLINICAL TRIAL FOR PRN1008 IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA PURPURADec 12, 2017
Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans ProgressivaDec 11, 2017
Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot StudyDec 11, 2017
Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology MeetingDec 11, 2017
Graybug Vision Expands Executive Leadership Team with Key HiresDec 11, 2017
resTORbio Appoints Paul Fonteyne to Its Board of DirectorsDec 9, 2017
ARMO BioSciences Presents Data from its Phase 1b Trial in Non-Small Cell Lung Cancer at ESMO Immuno Oncology Congress 2017Dec 9, 2017
Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host DiseaseDec 8, 2017
ARMO BioSciences Presents Efficacy Data from its Phase 1b Trial in Patients with Metastatic Renal Cell Carcinoma at ESMO Immuno-Oncology Congress 2017Dec 8, 2017
Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer SymposiumDec 8, 2017
Synlogic and Ginkgo Bioworks Announce Collaboration as First Step Toward Building an Unprecedented Discovery Engine for Novel Living Medicines in Neurological and Liver DisordersDec 7, 2017
Pieris Pharmaceuticals Announces Ethics And Regulatory Clearance To Begin Clinical Testing Of Inhaled Respiratory Program, Prs-060/Azd1402Dec 7, 2017
Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare ConferenceDec 7, 2017
TigerText Announces Patient Safety Committee, Partners with Geisinger and The George Washington University HospitalDec 6, 2017
Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor CellsDec 5, 2017
Sonendo® 2017 Red Herring Top 100 Global WinnerDec 5, 2017
Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot StudyDec 5, 2017
Multigene Genetic Testing Improves Identification and Management of Hereditary Cancer Risk for Breast Cancer Patients and Their FamiliesDec 5, 2017
ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm LaborDec 5, 2017
PMV Pharma Appoints Winston Kung as COO & CFODec 5, 2017
Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR022 for the Treatment of Atopic DermatitisDec 5, 2017
resTORbio Files Confidential Submission of Draft Registration Statement for Proposed Initial Public OfferingDec 4, 2017
Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion CancersDec 4, 2017
Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in AdultsDec 4, 2017
TP Therapeutics Appoints Sheila K. Gujrathi, MD to Board of Directors and as a Strategic AdvisorDec 4, 2017
Positive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual MeetingDec 1, 2017
NeuroPace Launches New RNS® Tablet at 2017 American Epilepsy Society Annual MeetingNov 30, 2017
Glaukos Announces Issuance of New U.S. PatentNov 30, 2017
resTORbio Raises $40 Million to Advance Selective TORC1 Inhibitors for Aging-Related Diseases and ConditionsNov 29, 2017
Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)Nov 29, 2017
scPharmaceuticals Inc. Announces Closing of Over-Allotment Option in its Initial Public OfferingNov 28, 2017
ARMO BioSciences Appoints Herb Cross as Chief Financial OfficerNov 28, 2017
TigerText Launches TigerFlow Enterprise – Healthcare’s Most Advanced Clinical Communication PlatformNov 21, 2017
Pieris Pharmaceuticals Appoints James Geraghty as Chairman of the Board of DirectorsNov 21, 2017
Audentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular MyopathyNov 21, 2017
Arvinas and Macroceutics Establish DEL Screening Collaboration on Undruggable TargetsNov 21, 2017
Realm Therapeutics Announces Publication of Positive Preclinical Data on PR022 in the Treatment of Atopic DermatitisNov 20, 2017
Arsanis Announces Closing of Initial Public OfferingNov 20, 2017
Cyrus Biotechnology Appoints Dr. David A Pearlman as Senior Fellow and Director of Customer ExperienceNov 20, 2017
Promentis Pharmaceuticals Commences Phase 1 Study for SXC-2023 Targeting Neuropsychiatric DisordersNov 20, 2017
resTORbio Advances to Part 2 of a Phase 2b Clinical Study of RTB101 ImmunotherapyNov 16, 2017
Ascendis Pharma A/S Reports Third Quarter 2017 Financial ResultsNov 16, 2017
scPharmaceuticals Inc. Announces Pricing of Initial Public OfferingNov 15, 2017
Arsanis Announces Pricing of Initial Public OfferingNov 15, 2017
Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information ServicesNov 15, 2017
Arvinas Expands Strategic License Agreement with GenentechNov 14, 2017
Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateNov 14, 2017
Aerpio Pharmaceuticals Announces Appointment of Michael Rogers as Chief Financial OfficerNov 14, 2017
Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195Nov 14, 2017
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business UpdateNov 14, 2017
Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial ResultsNov 14, 2017
Otsuka and Proteus® Announce the First U.S. FDA Approval of a Digital Medicine System: Abilify MyCite® (aripiprazole tablets with sensor)Nov 13, 2017
ViewRay Reports Third Quarter 2017 Financial ResultsNov 13, 2017
Audentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT342 to Treat Crigler-Najjar SyndromeNov 13, 2017
Aerpio Reports Third Quarter 2017 Financial ResultsNov 13, 2017
Alpine Immune Sciences reports corporate update and third quarter 2017 financia resultsNov 13, 2017
Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating OfficerNov 13, 2017
Synlogic Reports Third Quarter 2017 Financial Results and Recent ProgressNov 11, 2017
Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient SelectionNov 10, 2017
Washington University Completes Installation of Second MRIdian MR-Guided Radiotherapy System from ViewRayNov 10, 2017
Adaptimmune Presents Study Designs for Ongoing MAGE-A4 and NY-ESO SPEAR T-cell Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual MeetingNov 10, 2017
Alpine Immune Sciences presents preclinical data on novel immuno-oncology molecules at the Society for Immunotherapy of Cancers 32nd annual meetingNov 10, 2017
Promentis Pharmaceuticals to Present at Society for Neuroscience MeetingNov 9, 2017
Sanofi, Principia Agree to Develop Multiple Sclerosis Drug CandidateNov 9, 2017
NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune's SPEAR T-Cell TherapyNov 9, 2017
Nabriva Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate HighlightsNov 9, 2017
Avedro Marks the First Anniversary of Availability of the Only FDA Approved Corneal Cross-Linking Treatment in the U.S.Nov 8, 2017
Pieris Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2017, and Provides Corporate UpdateNov 8, 2017
Invitae Corporation Issues Reminder Regarding Exchange Offer for CombiMatrix Corporation Series F WarrantsNov 8, 2017
Tricida Announces Closing of $57.5 Million Series D FinancingNov 8, 2017
Sierra Oncology Reports Third Quarter ResultsNov 8, 2017
Synlogic Reports Positive Top-Line Phase 1 Data Demonstrating Safety and Tolerability and Proof of Mechanism in Healthy Volunteers for SYNB1020, a Synthetic BioticTM Medicine for the Treatment of HyperammonemiaNov 7, 2017
Glaukos Corporation Announces Third Quarter 2017 Financial ResultsNov 7, 2017
Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsNov 7, 2017
ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of EndometriosisNov 7, 2017
Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business UpdateNov 7, 2017
Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance TreatmentNov 7, 2017
Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017Nov 7, 2017
Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateNov 6, 2017
Adaptimmune marks Official Opening of U.K. HeadquartersNov 6, 2017
Invitae Reports Double-Digit Sequential Volume and Revenue Growth in Third Quarter 2017Nov 6, 2017
Alpine Immune Sciences presents ALPN-101 program data demonstrating potent preclinical activity in arthritis and inflammationNov 6, 2017
CTI BioPharma Reports Third Quarter 2017 Financial ResultsNov 3, 2017
ViewRay's MRIdian Linac Selected as MR-Guided Radiotherapy System in Danish TenderNov 3, 2017
Adaptimmune to Present Two Trials in Progress Posters at the Society for Immunotherapy of Cancer (SITC) Annual MeetingNov 3, 2017
Adaptimmune Data to be Presented in an Oral Presentation and a Trial in Progress Poster at the Connective Tissue Oncology Society (CTOS) Annual MeetingNov 2, 2017
Adaptimmune Reports Third Quarter 2017 Financial Results and Business UpdatesNov 2, 2017
Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual MeetingNov 2, 2017
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program UpdateNov 2, 2017
Loxo Oncology Announces Third Quarter 2017 Financial ResultsNov 2, 2017
Arvinas Nominates Oral Clinical Candidate for Androgen Receptor Degrader ProgramNov 2, 2017
scPharmaceuticals Announces FDA Acceptance of NDA for Furoscix (subcutaneous furosemide)Nov 1, 2017
Singulex announces 510(k) submission for the first ultra-sensitive cardiac troponin I (cTnI) test using Single Molecule Counting technologyNov 1, 2017
Intellia Therapeutics Announces Pricing of Public Offering of Common StockNov 1, 2017
Intellia Therapeutics Announces Proposed Public Offering of Common StockNov 1, 2017
Tricida Announces Podium Presentation at ASN Kidney Week 2017 of TRC101 Phase 1/2 Study Results in Patients with Metabolic Acidosis Associated with Chronic Kidney DiseaseOct 31, 2017
Intellia Therapeutics Announces Third Quarter 2017 Financial ResultsOct 31, 2017
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl SyndromeOct 31, 2017
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial ResultsOct 30, 2017
TELA Bio Announces Hiring of Greg Firestone as Vice President of Strategic Customer RelationsOct 30, 2017
Invitae Presents Validation of a Novel NGS-based Preimplantation Genetic Screening Technology to Identify the Most Frequent Chromosomal Causes of MiscarriageOct 30, 2017
Cyrus Bio Featured in US Pharmaceutical Industry Weekly ReportOct 30, 2017
Realm Therapeutics Presents Data Highlighting PR013's Efficacy Reducing Hyperemia and Pruritus Associated with Allergic Conjunctivitis at The American College of Allergy, Asthma, and Immunology (ACAAI) Scientific MeetingOct 30, 2017
Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development StrategyOct 27, 2017
ORIC Pharmaceuticals Announces First Subject Dosed in Phase 1 Clinical Study of Novel GR Antagonist with Planned Development for OncologyOct 25, 2017
Pacira Pharmaceuticals and TELA Bio Announce Equity AgreementOct 25, 2017
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYS™ (KPI-121 1%)Oct 25, 2017
Sierra Oncology Appoints Dr. Andrew Allen to its Board of DirectorsOct 24, 2017
Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's DiseaseOct 24, 2017
Acutus Medical® Receives FDA Clearance for Advanced Cardiac Mapping Technology for Complex ArrhythmiasOct 24, 2017
NeuroPace Closes $74 Million Equity Funding to Accelerate Patient Access to the World's First Brain-Responsive Neurostimulation System to Treat EpilepsyOct 24, 2017
Synlogic Receives Orphan Drug Designation for SYNB1618, a Synthetic BioticTM Medicine for the Treatment of PhenylketonuriaOct 24, 2017
ViewRay Raises $50 Million through Sale of Common StockOct 23, 2017
Intercept Announces Positive Results from Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis at The Liver Meeting® 2017Oct 23, 2017
Sébastien Desprez Joins Adaptimmune as Vice President of Communications and Investor RelationsOct 23, 2017
SI-BONE's New iFuse-NavigationTM Set* and iFuse-3DTM Fenestrated SI Joint Fusion Implant to be Featured at the 2017 North American Spine Society Annual MeetingOct 23, 2017
Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRsOct 18, 2017
Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual MeetingOct 18, 2017
Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib DatasetOct 17, 2017
Invitae data shows increased diagnosis rates with custom NGS technique allowing simultaneous genetic sequencing and copy number variant detectionOct 17, 2017
Cyrus Bio Leads Computational Protein Engineering PanelOct 17, 2017
Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical TrialOct 16, 2017
Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea's AEB1102 (pegzilarginase) with Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung CancerOct 16, 2017
Alpine Immune Sciences Announces Upcoming Scientific PresentationsOct 16, 2017
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017Oct 12, 2017
Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., As Vice President Of Clinical DevelopmentOct 11, 2017
Lupin Acquires Symbiomix Therapeutics LLCOct 10, 2017
Aerpio Pharmaceuticals Announces Appointment of Stephen Hoffman, M.D., Ph.D., as Chief Executive Officer and to the Board of Directors and the Transition of Joseph H. Gardner, Ph.D., to President and FounderOct 10, 2017
ObsEva SA Announces $60.0 Million Private Placement with Existing and New InvestorsOct 10, 2017
Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesOct 10, 2017
Synlogic Strengthens Leadership Team with Appointment of Chief Operating Officer and Chief Human Resources OfficerOct 9, 2017
ARMO BioSciences Appoints Immuno-Oncology Industry Veteran Joseph Leveque, M.D., as Chief Medical OfficerOct 9, 2017
Arsanis Presents Phase 1 and Preclinical Pharmacokinetic Data on Lead Product Candidate, ASN100, at IDWeek™ 2017Oct 9, 2017
SI-BONE, Inc. Announces Utah's Public Employees Health Plan (PEHP) Establishes Coverage for the iFuse ProcedureTM for Minimally Invasive SI Joint FusionOct 5, 2017
Glaukos iStent® Products to be Showcased at 2017 European Society of Cataract and Refractive SurgeryOct 5, 2017
Invitae's new framework for classifying genetic variants aims to improve consistency of genetic test results industry-wideOct 4, 2017
Arsanis Announces Appointments of Chip Clark and David McGirr to Board of Directors and Promotion of Michael Gray to Chief Operating Officer and Chief Financial OfficerOct 4, 2017
Samsung and TigerText Collaborate to Transform Healthcare Communications for CliniciansOct 3, 2017
Audentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT132 to Treat X-Linked Myotubular MyopathyOct 2, 2017
Pieris Pharmaceuticals Announces Dosing Of First Patient In Phase I Trial For Fully Proprietary Lead Io Program, Prs-343Oct 2, 2017
Dimension Board Determines That Ultragenyx's Unsolicited Proposal To Acquire Dimension For $6.00 Per Share Constitutes A "Superior Proposal"Sep 28, 2017
Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017Sep 28, 2017
Tricida Initiates Phase 3 Study of TRC101 for the Treatment of Metabolic Acidosis Associated With Chronic Kidney DiseaseSep 27, 2017
Audentes Therapeutics Announces Rare Pediatric Disease and Fast Track Designations for AT132 for the Treatment of X-Linked Myotubular MyopathySep 27, 2017
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSsSep 27, 2017
Loxo Oncology Announces Details of LOXO-292 Abstract to be Presented as Late-Breaking Presentation at the IASLC 18th World Conference on Lung CancerSep 27, 2017
KaNDy Therapeutics Launched to Focus on a Breakthrough New Product in Women's HealthSep 27, 2017
NeRRe Therapeutics appoints Andrew Kay as Chairman of the BoardSep 27, 2017
KaNDy Therapeutics launched to advance a breakthrough treatment in Women's HealthSep 27, 2017
Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to PatientsSep 26, 2017
Ascendis Pharma A/S Announces Proposed Public Offering of ADSsSep 26, 2017
Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTHSep 26, 2017
Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal StudySep 26, 2017
CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management PromotionsSep 25, 2017
Amarin and HLS Therapeutics Announce Agreement to Commercialize Vascepa® in CanadaSep 25, 2017
Intercept Statement Regarding Ocaliva® (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis (PBC) PatientsSep 25, 2017
SI-BONE, Inc. Announces Publication of iMIA – a 2nd Multicenter Randomized Controlled Trial of the iFuse Implant System® vs Conservative CareSep 25, 2017
SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical ProgramsSep 25, 2017
Pfizer launches upstart with $103M, phase 3-ready medsSep 25, 2017
Pfizer spends billions to develop new drugs. It's not satisfied. So it's launching a startupSep 25, 2017
SpringWorks Spins Out of Pfizer With $103M to Give Shelved Drugs New LifeSep 25, 2017
In A First, Pfizer Spins Out Biotech Firm With $103 Million In FundingSep 21, 2017
ViewRay MRIdian to be Featured in 21 Presentations from Seven Leading Centers at ASTROSep 21, 2017
Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular MyopathySep 20, 2017
Inspire Medical Systems' Inspire Therapy for Reducing Obstructive Sleep Apnea Demonstrates Long-Term Safety and Sustained Benefit Following 5- Years of TreatmentSep 20, 2017
Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual MeetingSep 20, 2017
Arvinas Appoints Dr. John Houston as President and Chief Executive OfficerSep 19, 2017
Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a �Superior Proposal�Sep 19, 2017
Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $80 MillionSep 19, 2017
Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular DegenerationSep 19, 2017
Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional sharesSep 18, 2017
Principia Biopharma Presents Late-Breaking Interim Phase 2 Data of PRN1008 in Pemphigus at European Academy of Dermatology and Venereology MeetingSep 18, 2017
Sonendo® announces growth investment from General AtlanticSep 18, 2017
FDA Approves Symbiomix Therapeutics' Solosec™ (secnidazole) Oral Granules for the Treatment of Bacterial Vaginosis in Adult WomenSep 18, 2017
Dimension Confirms Receipt of Unsolicited Proposal from UltragenyxSep 18, 2017
Nabriva Therapeutics Announces Proposed Public Offering of Ordinary SharesSep 18, 2017
Nabriva Therapeutics Announces Positive Topline Results from Global, Phase 3 Clinical Trial Evaluating IV and Oral Lefamulin for the Treatment of Community-Acquired Bacterial PneumoniaSep 15, 2017
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common StockSep 14, 2017
Glaukos to Outline Growth Strategy at Investor DaySep 14, 2017
Marinus Pharmaceuticals Announces Public Offering of Common StockSep 14, 2017
Sierra Oncology to Host KOL Call with Dr. Thomas Helleday presenting """"DNA Damage Response (DDR) Targets Beyond PARP""""Sep 13, 2017
Affimed Appoints Dr. Wolfgang Fischer as Chief Operating OfficerSep 13, 2017
Otonomy Provides Business and Financial UpdateSep 13, 2017
Invitae Highlighting New Research, Expanded Suite of Services at National Society of Genetic Counselors (NSGC) 36th Annual ConferenceSep 13, 2017
Loxo Oncology Announces Initial LOXO-292 Clinical Data to be Presented as Late-Breaking Presentation at the IASLC 18th World Conference on Lung CancerSep 12, 2017
Cerapedics Announces Publication of Two-Year IDE Study Follow-Up on i-FACTOR™ Bone Graft in the Cervical SpineSep 11, 2017
ObsEva SA Announces Presentation Related to its PGF2a Receptor Antagonist at ACCP 2017 Annual MeetingSep 11, 2017
Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for GanaxoloneSep 9, 2017
ARMO BioSciences's Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival in Patients with Advanced Pancreatic Cancer, NSCLC, and RCCSep 8, 2017
Singulex Receives New, Broad Patent for Digital Detection Of Cardiac Troponin-I Or Cardiac Troponin-T For Coronary Artery Disease Rule-OutSep 8, 2017
Arsanis Presents Preclinical Data on Lead Product Candidate, ASN100, at the “2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance”Sep 7, 2017
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESOSep 7, 2017
Summary ToggleSynlogic Presents New Preclinical Data at International Congress of Inborn Errors of MetabolismSep 7, 2017
Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)Sep 6, 2017
Symbiomix Therapeutics Announces Publication of Pivotal Phase 3 Data for Investigational Solosec™ for the Treatment of Bacterial VaginosisSep 6, 2017
Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 DeficiencySep 6, 2017
ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of ScheduleSep 5, 2017
Ascendis Pharma A/S Announces Presentations on Rare Disease Endocrinology Pipeline at Upcoming Medical ConferencesSep 5, 2017
ReViral initiates Phase 2a study of RV521 for treatment of Respiratory Syncytial VirusAug 31, 2017
Clementia Announces Data Presentations at Upcoming Medical Conferences in SeptemberAug 31, 2017
Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) DeficiencyAug 31, 2017
Nabriva Therapeutics Announces Resignation of Elyse Seltzer, M.D.Aug 30, 2017
Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's DiseaseAug 30, 2017
Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote SpeakerAug 29, 2017
ARMO BioSciences Raises $67 Million in a Series C-1 FinancingAug 28, 2017
Synlogic Completes Merger with Mirna TherapeuticsAug 25, 2017
REGENXBIO to Acquire Dimension TherapeuticsAug 23, 2017
SI-BONE, Inc. Announces Highmark, Inc., 4th Largest Blue Cross Blue Shield Plan and 10th Largest U.S. Commercial Payor, Establishes Positive Coverage Policy for Minimally Invasive Sacroiliac Joint Fusion Exclusively for the iFuse Implant System®Aug 22, 2017
Avitide, Inc., Receives Iso 9001:2015 Certification For Its Affinity Resin Manufacturing FacilityAug 21, 2017
Clementia Announces Closing of Over-Allotment Option in its Initial Public OfferingAug 18, 2017
Ascendis Pharma A/S Reports Second Quarter 2017 Financial ResultsAug 17, 2017
Roka Bioscience, Inc. Agrees to Sell its Assets to Subsidiary of Institute for Environmental Health, Inc.Aug 15, 2017
ObsEva Reports Second Quarter 2017 Financial Results and Provides Business UpdateAug 15, 2017
Sierra Oncology Establishes Distinguished DNA Damage Response Advisory CommitteeAug 14, 2017
Aerpio Reports Second Quarter 2017 Financial ResultsAug 10, 2017
Pieris Pharmaceuticals Appoints Allan Reine, M.D., as Chief Financial OfficerAug 10, 2017
Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate UpdateAug 10, 2017
Symbiomix Therapeutics Presents New Data on Solosec™Aug 10, 2017
Sierra Oncology Reports Second Quarter 2017 ResultsAug 9, 2017
Pieris Pharmaceuticals Reports Financial Results for the Second Quarter Ended June 30, 2017 and Provides Corporate UpdateAug 9, 2017
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial ResultsAug 9, 2017
SI-BONE, Inc. Announces Publication of a Level I Study Demonstrating Strong Clinical Prediction for the Diagnosis of SI Joint DysfunctionAug 8, 2017
Aerpio Pharmaceuticals Commences Trading on the OTCQB® MarketAug 8, 2017
Dimension Therapeutics Reports Second Quarter 2017 Financial Results And Provides Corporate UpdateAug 8, 2017
Loxo Oncology Announces Second Quarter 2017 Financial ResultsAug 8, 2017
Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development UpdateAug 7, 2017
ViewRay Reports Second Quarter 2017 Financial ResultsAug 7, 2017
Invitae Reports Second Quarter 2017 ResultsAug 7, 2017
Nabriva Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate HighlightsAug 3, 2017
Early Clinical Experience with ViewRay's MRIdian Linac Presented at Leading Medical Physics MeetingAug 3, 2017
Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate UpdateAug 3, 2017
Adaptimmune Reports Second Quarter 2017 Financial ResultsAug 3, 2017
Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business UpdateAug 3, 2017
Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of LifeAug 3, 2017
Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate UpdateAug 2, 2017
Amoy Diagnostics Co., Ltd. Starts IPO on Shenzhen Stock ExchangeAug 2, 2017
Glaukos Corporation Announces Second Quarter 2017 Financial ResultsAug 2, 2017
SI-BONE, Inc. Announces Publication of iMIA – a 2nd Multicenter Randomized Controlled Trial of the iFuse Implant System® vs Conservative CareAug 2, 2017
Results from Avedro's Corneal Collagen Cross-Linking Pivotal Phase 3 Corneal Ectasia Studies Published in OphthalmologyAug 2, 2017
CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphomaAug 1, 2017
Affimed Reports Financial Results for Second Quarter 2017Aug 1, 2017
Evaluations of the Analytical Performance of the Singulex Cardiac Troponin I Assay Used on its Single Molecule Counting Technology Platform Demonstrates Ability to Improve Cardio Vascular Disease Rule-OutAug 1, 2017
Keystone Heart Ltd to Accelerate Trials for Advanced Device to Protect Brain During Heart ProceduresAug 1, 2017
Intellia Therapeutics Announces Second Quarter 2017 Financial ResultsAug 1, 2017
Rhythm Expands Executive Leadership TeamAug 1, 2017
CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with RuxolitinibAug 1, 2017
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial ResultsJul 31, 2017
Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of LifeJul 31, 2017
Intercept Announces Positive Results from the Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing CholangitisJul 31, 2017
Loxo Oncology Announces Acquisition of Highly Selective, Reversible BTK Inhibitor ProgramJul 27, 2017
Cyrus Biotechnology Announces $8M Financing to Expand Computational Drug Discovery Software PlatformJul 26, 2017
Sientra Completes Acquisition of Miramar Labs®Jul 26, 2017
Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance TreatmentJul 25, 2017
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene EditingJul 25, 2017
Alpine Immune Sciences, Inc. Completes Merger with Nivalis Therapeutics, Inc.Jul 25, 2017
Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters' OptionJul 24, 2017
Dimension Therapeutics Announces Management ChangeJul 21, 2017
Leading Medical Physics Meeting to Feature First Presentations on Clinical Experience with ViewRay's MRIdian LinacJul 21, 2017
Pharming announces completion of its refinancing with a single US$100 million debt facility on improved commercial termsJul 20, 2017
First Patients Treated with ViewRay's MRIdian Linac System at Henry Ford Health SystemJul 20, 2017
Aeglea BioTherapeutics Announces Leadership ChangeJul 20, 2017
Kala Pharmaceuticals Announces Pricing of Initial Public OfferingJul 18, 2017
Adimab Announces Platform Transfer with LillyJul 18, 2017
Audentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, EuropeJul 18, 2017
Otonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Application Filing for Acute Otitis ExternaJul 18, 2017
Augmedix, powered by Glass, accelerates scaling efforts with the nation's leading healthcare systemsJul 17, 2017
Symbiomix Therapeutics Announces Publication of Pivotal Data for Investigational Solosec™ for the Treatment of Bacterial VaginosisJul 13, 2017
CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have ThrombocytopeniaJul 11, 2017
Roka Bioscience Announces AOAC Certification for 18-hour Sample Enrichment using ActeroTM ELITE Listeria Enrichment Media and the Atlas® Listeria Environmental AssayJul 11, 2017
Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA For Treatment of Pemphigus VulgarisJul 11, 2017
Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial OfficerJul 10, 2017
Roka Bioscience, Inc. Announces Co-Marketing and Supply Agreement with PURE BioscienceJul 10, 2017
Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical OfficerJul 6, 2017
Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-OncologyJul 5, 2017
Pieris Pharmaceuticals Announces Results from 2017 Annual Meeting of Stockholders and Provides Update on Therapeutic ProgramsJul 5, 2017
SmartZyme Adds Two Drug Development Veterans to Broaden and Strengthen Leadership TeamJun 30, 2017
SteadyMed submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead drug product candidate, Trevyent, for the treatment of Pulmonary Arterial Hypertension (PAH).Jun 29, 2017
ARMO BioSciences Presents Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer at ESMO World Congress on Gastrointestinal Cancer 2017Jun 29, 2017
Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic RetinopathyJun 29, 2017
ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual MeetingJun 29, 2017
FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 DisorderJun 28, 2017
Adicet Bio Appoints Jesse McGreivy, M.D., Chief Medical OfficerJun 28, 2017
FutuRx portfolio cpmany, Mitoconix Bio gets $20M for mitochondrial dysfunction in neurodegenerationJun 27, 2017
Affimed Presents Preclinical Data on AFM24 and AFM26 at EACR-AACR-SIC 2017Jun 27, 2017
Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across EuropeJun 27, 2017
Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary EndpointJun 27, 2017
Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of ObesityJun 27, 2017
Dimension Therapeutics Completes Strategic Review And Updates Corporate PrioritiesJun 27, 2017
Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum DepressionJun 27, 2017
TP Therapeutics Announces FDA Orphan Drug Designation Granted to TPX-0005 for Treatment of Non-Small Cell Lung Adenocarcinomas Harboring ALK, ROS1, or NTRK Oncogenic RearrangementsJun 27, 2017
LogicBio Therapeutics Announces $50 Million in Financing to Develop Novel Gene Medicines for Pediatric PatientsJun 26, 2017
Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the BoardJun 26, 2017
Synlogic Receives Fast Track Designation in U.S. for Lead Candidate, SYNB1020Jun 26, 2017
National Cancer Center Japan Treats First Patients Using ViewRay MRIdian SystemJun 22, 2017
Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy TubesJun 21, 2017
Combining Implantation of Glaukos iStent inject® Trabecular Micro-Bypass with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile, According to New StudyJun 21, 2017
Avitide, Inc., Raises Series E Financing From Sands Capital Ventures With Broad Participation From Early InvestorsJun 21, 2017
Adimab Provides Mid-Year Update on 2017 Partnership ActivityJun 20, 2017
Loxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional SharesJun 20, 2017
Avedro Names Thomas E. Griffin Chief Financial OfficerJun 19, 2017
Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in ChinaJun 19, 2017
Synlogic™ Doses First Subject in Phase 1 Trial of Novel Class of Synthetic Biotic™ MedicinesJun 16, 2017
Tisbury Pharmaceuticals Raises $32M in Series A FinancingJun 15, 2017
RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA�) for H. pylori InfectionJun 14, 2017
RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA for Acute GastroenteritisJun 14, 2017
Alpine Immune Sciences Announces Presentation of Preclinical Data Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vlgDs in an Animal ModelJun 13, 2017
SI-BONE, Inc. Announces FDA Clearance and Full U.S. Commercial Launch of the iFuse-3DTM Implant, a Patented, 3D-Printed Next Generation Member of the iFuse Implant SystemJun 13, 2017
Abbvie And Principia Announce Collaboration On Oral Immunoproteasome InhibitorsJun 13, 2017
Audentes Therapeutics Appoints Jennifer Jarrett to Board of DirectorsJun 12, 2017
Sientra to Acquire Miramar LabsJun 12, 2017
Intercept Announces New Data Analysis From FLINT Trial of OCA in NASH Patients with Type 2 DiabetesJun 12, 2017
SI-BONE, Inc. Announces Blue Cross and Blue Shield of Vermont Establishes Positive Coverage Policy for MIS Sacroiliac Joint FusionJun 12, 2017
Invitae Acquires CancerGene Connect, Award-Winning Risk Assessment and Family History Analysis PlatformJun 9, 2017
MEDIGUS PRESENTS NEW DATA DEMONSTRATING THE MUSE™ SYSTEM IMPROVES GERD SYMPTOMS AND REDUCES PROTON PUMP INHIBITOR RELIANCEJun 8, 2017
Intellia’s Response to Nature Methods Article on CRISPR/Cas9Jun 7, 2017
ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back TherapyJun 6, 2017
Synlogic Meets First Discovery Milestone in Partnership with AbbVieJun 6, 2017
Aeglea BioTherapeutics Prices Public Offering of Common StockJun 6, 2017
Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017Jun 5, 2017
Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials of Chk1 Inhibitor SRA737Jun 5, 2017
Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual MeetingJun 5, 2017
ASCO Data Shows Prostate Cancer Patients with Genetic Risk Factors Missed Under Current Testing GuidelinesJun 5, 2017
Corvus Pharmaceuticals Announces Interim Results Demonstrating Anti-Tumor Activity of CPI-444 in Renal and Lung Cancer Patients Resistant or Refractory to Prior PD-(L)1 TreatmentJun 5, 2017
Inspire Medical Systems Announces FDA Approval of Inspire 3028 Neurostimulator for the Treatment of Obstructive Sleep ApneaJun 5, 2017
TELA Bio to Present Surgeon Feedback from Initial Clinical Experience with OviTex™ Reinforced BioScaffolds and Product Permeability Data at Abdominal Wall Reconstruction ConferenceJun 5, 2017
Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDAJun 4, 2017
Pieris Pharmaceuticals Announces Presentation Of Clinical Data For Anemia Drug Candidate, PRS-080, At The 54Th ERA-EDTA CongressJun 3, 2017
ARMO BioSciences Announces Encouraging Survival Data Observed in Patients with Advanced Pancreatic Cancer in Phase 1/1b Trial of Immunotherapy AM0010Jun 3, 2017
Loxo Oncology Announces Clinical Proof of Concept Publication for Next-Generation TRK Inhibitor LOXO-195Jun 3, 2017
Loxo Oncology Breakthrough Therapy Larotrectinib Demonstrates 76 Percent Confirmed Objective Response Rate in TRK Fusion Adult and Pediatric Cancers as Presented at the American Society of Clinical OncologyJun 2, 2017
Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulinJun 1, 2017
Results from Avedro's Landmark Corneal Collagen Cross-Linking Pivotal Phase 3 Keratoconus Studies Published in OphthalmologyJun 1, 2017
BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination with Atezolizumab for Solid TumorsMay 30, 2017
Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737May 26, 2017
STEADYMED RAISES ADDITIONAL CAPITAL FROM KEY INSTITUTIONAL SHAREHOLDERMay 23, 2017
Atox Bio’s Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as PlannedMay 23, 2017
Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North TherapeuticsMay 23, 2017
Ascendis Pharma A/S Reports First Quarter 2017 Financial ResultsMay 23, 2017
Nabriva Commences Previously Announced Tender Offer Related to the Proposed Redomicile of its Holding Company from Austria to IrelandMay 22, 2017
Pieris Pharmaceuticals Appoints James Geraghty to its Board of DirectorsMay 22, 2017
Study Reveals Potential Cost Efficiency of Using Two Glaukos iStent® Trabecular Micro-Bypass Stents to Treat Elevated IOP in Glaucoma PatientsMay 19, 2017
Intercept Receives Innovation Award from the National Organization for Rare Disorders for the Development of Ocaliva® (obeticholic acid)May 18, 2017
Verona Pharma Announces Closing of Exercise of Underwriters’ Over-allotment OptionMay 18, 2017
ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022May 18, 2017
ObsEva Reports First Quarter 2017 Financial Results and Business UpdateMay 17, 2017
Affimed Reports Financial Results for First Quarter 2017May 17, 2017
Loxo Oncology Announces Details of Two Larotrectinib Clinical Data Oral Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual MeetingMay 17, 2017
Rhythm Expands Phase 2 Clinical Trials of Setmelanotide to the Treatment of Bardet-Biedl Syndrome ObesityMay 17, 2017
Affimed to Present Immune Cell Engager Data at ASCO Annual Meeting and EACR-AACR-SIC Special ConferenceMay 16, 2017
Pharming announces refinancing of its existing debt by a single US$100 million debt facility on improved commercial termsMay 16, 2017
Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid TumorsMay 16, 2017
Practice Fusion to Present Real World Data on the Treatment of Diabetes and COPD at the ISPOR 22nd Annual International MeetingMay 16, 2017
Synlogic and Mirna Therapeutics Agree to MergerMay 16, 2017
5/16/17 - Aerpio Reports First Quarter 2017 Financial ResultsMay 15, 2017
Compelling Early Pancreatic Cancer Data with ViewRay’s MRIdian System Presented at ESTRO 36May 15, 2017
ViewRay Reports First Quarter 2017 Financial ResultsMay 15, 2017
Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 in Renal and Lung Cancer at 2017 ASCO Annual MeetingMay 13, 2017
Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual MeetingMay 12, 2017
Loxo Oncology Announces FDA Orphan Drug Designation Granted to Larotrectinib for the Treatment of Solid Tumors with NTRK-Fusion ProteinsMay 12, 2017
Otonomy Announces OTIPRIO® Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual MeetingMay 11, 2017
Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide for Rare Genetic Disorders of ObesityMay 11, 2017
Good Start Genetics Deepens Relationship with Amazon offering a First of its Kind Online Ashkenazi Jewish Carrier Screening Test - See more at: https://www.goodstartgenetics.com/media-investors/genetic-screening-news/#sthash.D5vt0De1.dpufMay 11, 2017
Roka Bioscience Reports First Quarter 2017 Financial ResultsMay 11, 2017
Guardant Health Partners with SoftBank to Accelerate Efforts in Early Cancer DetectionMay 11, 2017
Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate UpdateMay 11, 2017
FutuRx portfolio cpmany, BiomX Ltd. has secured $24 million in a Series A financingMay 10, 2017
Otic Pharma Completes Merger with Tokai Pharmaceuticals Company Renamed Novus Therapeutics, Inc; NASDAQ Ticker "NVUS"May 10, 2017
Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver CancerMay 10, 2017
Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate UpdateMay 10, 2017
Loxo Oncology Announces Enrollment of First Patient in Phase 1 Clinical Trial for Highly Selective RET Inhibitor, LOXO-292May 10, 2017
Pieris Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2017 and Provides Corporate UpdateMay 10, 2017
Adaptimmune Reports First Quarter 2017 Financial ResultsMay 10, 2017
Sierra Oncology Receives Clearance to Enhance Ongoing Clinical Trials for SRA737May 9, 2017
Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate UpdateMay 9, 2017
Sierra Oncology Reports First Quarter 2017 ResultsMay 9, 2017
Loxo Oncology Announces First Quarter 2017 Financial ResultsMay 9, 2017
Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial ResultsMay 9, 2017
Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology ProgramMay 8, 2017
Graybug Vision’s Potential Once-Per-Year AMD Treatment Data Presented at ARVO 2017May 8, 2017
SI-BONE, Inc. Announces U.S. Military's TRICARE Now Covers MIS SI Joint FusionMay 8, 2017
Roka Bioscience, Inc. Announces Distribution Partnership with FoodChek Systems Inc.May 8, 2017
Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific OfficerMay 8, 2017
Valerie Smith Joins Graybug Vision as VP, Global Clinical Development OperationsMay 8, 2017
Invitae Exceeds 26,000 Samples Accessioned, Reports Revenue of $10.3 Million and Net Loss of $0.64 Per Share in First Quarter 2017May 4, 2017
Intercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business UpdateMay 4, 2017
Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate UpdateMay 4, 2017
Rhythm Starts Phase 3 Clinical Trial of Setmelanotide for Rare Genetic Disorder of ObesityMay 4, 2017
Avedro Launches Comprehensive Effort to Secure Coverage and Facilitate Reimbursement of FDA-Approved Corneal Cross-Linking TreatmentMay 4, 2017
Corvus Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business UpdateMay 3, 2017
Pieris Pharmaceuticals and AstraZeneca Collaborate to Develop and Commercialize Anticalin-Based Inhaled Treatments for Respiratory DiseasesMay 3, 2017
Glaukos Corporation Announces First Quarter 2017 Financial ResultsMay 3, 2017
Audentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual MeetingMay 3, 2017
Glaukos Completes Patient Enrollment in Phase II Clinical Trial for iDose™ Travoprost Intraocular Implant in Glaucoma PatientsMay 3, 2017
BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDAMay 3, 2017
Acutus Medical® Receives FDA Clearance for AcQGuide™ Steerable SheathMay 2, 2017
SteadyMed Receives USPTO Notice of Allowance for Patent Related to Key PatchPump® TechnologyMay 2, 2017
Intellia Therapeutics Announces First Quarter 2017 Financial ResultsMay 2, 2017
Corvus Pharmaceuticals Expands CPI-444 Clinical Collaboration with GenentechMay 2, 2017
ViewRay Showcases World’s First Commercially Available MRI-Guided Linac System at Leading European Radiation Oncology MeetingMay 2, 2017
Roka Bioscience to Present and Exhibit at the 2017 Food Safety SummitMay 2, 2017
Verona Pharma Announces Closing of Global OfferingMay 1, 2017
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial ResultsMay 1, 2017
Several Surgeon Presentations to Include Glaukos Technologies at 2017 American Society of Cataract and Refractive SurgeryMay 1, 2017
SI-BONE, Inc. Announces SI Joint Fusion Study Showed Patients Were 11X Less Likely to be Taking Opioids at Last Follow-Up Using the iFuse ImplantMay 1, 2017
Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract SurgeryApr 28, 2017
New research suggests current genetic testing guidelines may miss breast cancer patients who could benefit from testingApr 28, 2017
Acutus Medical® Announces Completion of Enrollment for UNCOVER AF™ Study of AcQMap® in Persistent Atrial FibrillationApr 27, 2017
Avedro Announces $42 Million in Funding to Support Commercial Expansion and Pipeline DevelopmentApr 26, 2017
Arsanis Completes $45.5 Million Series D FinancingApr 26, 2017
Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of EpilepsyApr 26, 2017
Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein ComplexesApr 26, 2017
John Tucker Appointed as Chief Executive Officer of scPharmaceuticalsApr 25, 2017
ObsEva SA Initiates Phase 3 Clinical Program for OBE2109 in Uterine FibroidsApr 24, 2017
Allied Physicians Group and Tyto Care Sign Agreement to Bring Remote Telehealth Exams to Allied’s Vast Network of PatientsApr 24, 2017
ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy VolunteersApr 24, 2017
SI-BONE, Inc. Announces Publication of 6-year Clinical Results Demonstrating Long-Term Positive Outcomes of iFuse Implant SystemApr 24, 2017
Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual MeetingApr 24, 2017
Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in ChinaApr 24, 2017
RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-DApr 21, 2017
STEADYMED RAISES $30 MILLION IN PRIVATE PLACEMENTApr 20, 2017
ARMO BioSciences Announces Clinical Data Presentations for Immunotherapy AM0010 at ASCO 2017 Annual MeetingApr 20, 2017
Invitae announces expansion of its genetic test menu with addition of new tests and expanded panels for inherited metabolic and immune system disorders, including panels to confirm diagnoses suggested by newborn screeningApr 20, 2017
Arsanis Announces Initial Clinical Data for ASN100 to be Presented at the 27th European Congress of Clinical Microbiology and Infectious DiseasesApr 19, 2017
Oxford Finance Provides $20 Million Senior Debt Facility to Cerapedics IncApr 19, 2017
Verona Pharma Announces Launch of Global Offering and Application to List on the NASDAQ Global MarketApr 19, 2017
Intercept Announces New Ocaliva® (obeticholic acid) and INT-767 Data to be Presented at EASL 2017Apr 18, 2017
Audentes Therapeutics Announces Pricing of Public Offering of Common StockApr 18, 2017
Nivalis Therapeutics and Alpine Immune Sciences agree to combineApr 18, 2017
Verona Pharma Receives Authorization from the U.S. FDA to Proceed with Clinical Investigation of RPL554 with the Acceptance of Investigational New Drug ApplicationApr 17, 2017
Singulex Announces $50 Million Senior Secured Debt Facility with Perceptive AdvisorsApr 17, 2017
Nabriva Announces the Proposed Redomicile of its Holding Company from Austria to Ireland, by means of an Exchange OfferApr 13, 2017
International Study Shows Two Glaukos iStent® Trabecular Micro-Bypass Stents and One Topical Medication Deliver Sustained IOP ReductionApr 13, 2017
ViewRay Announces $15.0 Million Capacity Expansion of its Term Loan AgreementApr 13, 2017
Miami Children’s Health System and Tyto Care to Expand Telehealth Services for Home ConsumersApr 13, 2017
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board DecisionApr 12, 2017
Glaukos Corporation Acquires IOP Sensor System from DOSE MedicalApr 11, 2017
Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical OfficerApr 11, 2017
Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial PneumoniaApr 11, 2017
Intellia Therapeutics Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology PatentApr 11, 2017
Tricida Announces Hiring of Geoffrey Parker as Chief Financial Officer and Senior Vice PresidentApr 11, 2017
Rhythm Appoints Head of Sanofi Genzyme, Dr. David Meeker, as Chairman of Board of DirectorsApr 10, 2017
Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct OfferingApr 10, 2017
Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical ConferenceApr 9, 2017
CE MARK GRANTED TO NUCLEIX’S BLADDER EPICHECK – ANNOUNCING SUPERIOR RESULTS OVER ALL OTHER NON-INVASIVE TESTS IN A EUROPEAN MULTI-CENTER STUDY FOR BLADDER CANCER MONITORINGApr 7, 2017
SI-BONE, Inc. Announces Published Guidance Recommendation for Minimally Invasive SI Joint Fusion from the National Institute for Health and Care Excellence (NICE)Apr 6, 2017
Invitae expands its Genome Network with the launch of the Invitae Patient Insights Network (PIN), enabling participants to share health information and contribute to researchApr 5, 2017
Practice Fusion Names Seasoned Health IT Executive Bevey Miner as New Chief Marketing OfficerApr 5, 2017
RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGamApr 5, 2017
True North Expands Leadership Team to Advance Pipeline of Novel Rare Disease Treatments Targeting the Complement SystemApr 5, 2017
Affimed Presents Data on Immune Cell Engager Pipeline at the AACR Annual Meeting 2017Apr 4, 2017
Pieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, in Poster Session at the 2017 Meeting of the American Association for Cancer Research (AACR)Apr 4, 2017
Corvus Pharmaceuticals Announces Interim Results from Ongoing Phase 1/1b Study Demonstrating Safety and Clinical Activity of Lead Checkpoint Inhibitor CPI-444 in Patients with Advanced CancersApr 3, 2017
Singulex Announces CE Mark for Sgx Clarity® SystemApr 3, 2017
Sierra Oncology Collaborator ICR Reports Preclinical Synthetic Lethality Data for Chk1 Inhibitor SRA737 at AACRApr 3, 2017
SI-BONE, Inc. Announces 50th Peer-Reviewed Publication for the iFuse Implant System® and 25,000th iFuse Procedure Performed WorldwideApr 3, 2017
Ascendis Pharma A/S Showcases New Data on Rare Disease Product Pipeline at ENDO 2017Apr 3, 2017
Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular MyopathyApr 3, 2017
Invitae announces new partnership with Alnylam Pharmaceuticals to provide TTR gene testing for patients suspected of having hereditary ATTR amyloidosisMar 31, 2017
Loxo Oncology Announces Proof of Concept Clinical Data for Larotrectinib in TRK Fusion Glioblastoma Presented at the AACR Annual Meeting 2017Mar 30, 2017
GE Healthcare & Zai Lab Enter a Strategic Partnership to Co-Develop a World Class Biotherapeutics Clinical Production CenterMar 30, 2017
Promentis Pharmaceuticals, Inc. Announces $26M Series C Financing and Elects Four New Board MembersMar 29, 2017
Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual MeetingMar 29, 2017
ARMO BioSciences Announces First Patient Dosed in Pivotal Phase 3 Trial of Immunotherapy AM0010 for Advanced Pancreatic CancerMar 28, 2017
Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive TrendsMar 24, 2017
EU-funded consortium led by Immatics and BioNTech announces completion of regular study treatment in the GAPVAC-101 trialMar 23, 2017
Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics MeetingMar 23, 2017
Singulex Expands Collaboration with European Clinical Laboratories to Demonstrate Applications and Opportunity of Sgx ClarityTM SystemMar 23, 2017
Symbiomix Therapeutics Announces FDA’s Acceptance of New Drug Application for Solosec™ with Priority Review StatusMar 23, 2017
Affimed Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Conference CallMar 23, 2017
Invitae Expands Test Menu for Proactive Genetic Testing in Healthy AdultsMar 22, 2017
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary SharesMar 22, 2017
Pieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate UpdateMar 22, 2017
Ascendis Pharma A/S Reports Full Year 2016 Financial ResultsMar 22, 2017
Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics MeetingMar 22, 2017
Synlogic to Present at 2017 American College of Medical Genetics and Genomics Annual MeetingMar 22, 2017
Leading Family Genomics Company Good Start Genetics Expands Payor Relationships to More than 130 Million Covered LivesMar 21, 2017
argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseasesMar 20, 2017
Loxo Oncology Announces Larotrectinib Pan-TRK IHC Companion Diagnostic Collaboration with Ventana Medical Systems, Inc., a member of the Roche GroupMar 20, 2017
Corvus Pharmaceuticals to Present Data That Advances the Understanding of the Adenosine Pathway in Immuno-Oncology, including New Clinical Data on CPI-444 at AACR 2017Mar 20, 2017
Audentes Therapeutics Announces Presentation Of Data From RECENSUS, A Medical Chart Review Of Patients With X-Linked Myotubular Myopathy (XLMTM)Mar 17, 2017
ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm LaborMar 16, 2017
ViewRay Reports Fourth Quarter and Full Year 2016 Financial ResultsMar 16, 2017
Glaukos Announces Five-Year Extensions for Three Category III CPT Codes Related to Micro-Invasive Glaucoma SurgeryMar 16, 2017
Aerpio Pharmaceuticals Raises $40 MillionMar 15, 2017
argenx reports fourth quarter business update and full year 2016 financial resultsMar 15, 2017
Adaptimmune Broadens Executive TeamMar 14, 2017
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial ResultsMar 14, 2017
Invitae to present seventeen posters and presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics MeetingMar 13, 2017
Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial ResultsMar 13, 2017
NeRRe Therapeutics appoints Dr Steve Pawsey as Chief Medical OfficerMar 13, 2017
Marinus Pharmaceuticals Provides Business Update and 2016 Financial ResultsMar 10, 2017
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business UpdateMar 9, 2017
Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate UpdateMar 9, 2017
Roka Bioscience Reports Fourth Quarter and Full Year 2016 Financial ResultsMar 9, 2017
Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa ManufacturingMar 8, 2017
Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery TechnologyMar 8, 2017
SI-BONE, Inc. Launches SI Joint Women's Health Initiative at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego, March 14 - 17Mar 8, 2017
Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate UpdateMar 7, 2017
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ARTMar 7, 2017
Loxo Oncology Reports Fourth Quarter and Year-End 2016 Financial ResultsMar 6, 2017
argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemiaMar 6, 2017
Keystone Heart Applauds FDA Advisory PanelMar 6, 2017
Keystone Heart and Venus MedTech Announce Partnership for Cerebral Embolic Protection with Transcatheter Heart Valve Systems (TAVR) in China and Key Asian MarketsMar 6, 2017
Pieris Pharmaceuticals Announces Presentation of IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2017 Meeting of the American Association for Cancer Research (AACR)Mar 2, 2017
NICE Recommends Ocaliva® (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern IrelandMar 2, 2017
Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate UpdateMar 2, 2017
Sierra Oncology Reports 2016 Year-End ResultsMar 1, 2017
argenx announces intention to conduct a registered public offering in the United StatesMar 1, 2017
Glaukos Corporation Announces Fourth Quarter & Full Year 2016 Financial ResultsMar 1, 2017
Adaptimmune Cuts Ribbon on U.S. Headquarters at the Navy Yard in PhiladelphiaMar 1, 2017
Audentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1 / 2 Run-in Study of Patients with Crigler-Najjar SyndromeFeb 28, 2017
Glaukos Technologies Featured in Eight Presentations at 2017 American Glaucoma Society MeetingFeb 28, 2017
Ascendis Pharma A/S Announces Multiple Poster Presentations at ENDO 2017Feb 27, 2017
ArGEN-x announces extension of therapeutic antibody alliance with ShireFeb 27, 2017
ViewRay Receives FDA 510(k) Clearance for MRIdian LinacFeb 27, 2017
Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal AntibodiesFeb 27, 2017
Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal AntibodiesFeb 27, 2017
PIERIS SIGNS 1ST PARTNERSHIP FOR ANEMIA DRUG PRS-080, GRANTING EXCLUSIVE OPTION IN JAPAN TO ASKA PHARMACEUTICALFeb 23, 2017
Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business UpdateFeb 22, 2017
Preeminent Ophthalmologist, L. Jay Katz Joins Glaukos Corporation as Chief Medical OfficerFeb 22, 2017
Symbiomix Therapeutics Appoints David L. Stern as Chief Executive OfficerFeb 22, 2017
PMV Pharma Secures $74 Million in Series B Financing for Cancer Drugs Targeting p53Feb 21, 2017
Loxo Oncology Announces Completion of Clinical Trial Enrollment for Larotrectinib NDA Primary Efficacy AnalysisFeb 17, 2017
New research suggests broader genetic testing of prostate cancer patients may be warranted to identify risk of an inherited mutation that might inform treatmentFeb 17, 2017
Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC at ASCO 2017 Genitourinary Cancers SymposiumFeb 16, 2017
Rhythm Announces Completion of $41 Million Mezzanine FinancingFeb 16, 2017
TigerText Launches Role-based Scheduling AutomationFeb 16, 2017
Glaukos Completes Patient Enrollment in Pivotal Phase of U.S. IDE Clinical Trial for iStent SUPRA®Feb 16, 2017
Ascendis Pharma A/S Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric PatientsFeb 15, 2017
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.Feb 14, 2017
Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical ModelFeb 14, 2017
Practice Fusion Launches EHR-integrated Post-Marketing Active Safety Surveillance ProgramFeb 13, 2017
Invitae reports revenue of $9.2 million in fourth quarter 2016 and projects strong volume and revenue growth in 2017Feb 13, 2017
RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute GastroenteritisFeb 10, 2017
Intercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid for the Treatment of NASH Patients with Liver FibrosisFeb 8, 2017
New Study at Leading Children’s Medical Center Finds TytoCare Telehealth Exams Equivalent to In-Clinic ExamsFeb 7, 2017
Pieris Announces Management TransitionFeb 6, 2017
Sonendo® Acquires PIPStek™ LLCFeb 6, 2017
Joseph Gilliam to Join Glaukos Corporation as Chief Financial Officer and Senior Vice President of Corporate DevelopmentFeb 2, 2017
Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial PneumoniaFeb 1, 2017
Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar SyndromeFeb 1, 2017
Glaukos Corporation Promotes Chris M. Calcaterra to Chief Operating OfficerJan 31, 2017
DIMENSION ANNOUNCES INTERIM TOPLINE RESULTS FROM ONGOING PHASE 1/2 CLINICAL PROGRAM FOR DTX101, DIMENSION’S LEAD AAV PRODUCT CANDIDATE IN DEVELOPMENT FOR ADULT PATIENTS WITH MODERATE/SEVERE TO SEVERE HEMOPHILIA BJan 27, 2017
Private Japanese Hospital Purchases ViewRay MRIdian SystemJan 25, 2017
ObsEva SA Announces Pricing of Initial Public OfferingJan 25, 2017
"Affimed Announces Closing of Public Offering of Common Stock"Jan 25, 2017
Roka Bioscience To Exhibit And Present At IPPE 2017 Poultry ExpoJan 24, 2017
scPharmaceuticals Announces Start of SUBQ-HF NHLBI Study with Its Subcutaneous Furosemide ProductJan 24, 2017
Arsanis Announces First Patient Dosed in Global Phase 2 Study of ASN100 for Prevention of Staphylococcus aureus PneumoniaJan 23, 2017
FierceMedicalDevices names Acutus Medical® as one of its “Fierce 15” Medical Device Companies of 2016Jan 23, 2017
Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic DisorderJan 23, 2017
SI-BONE's iFuse Implant System® Requires Revision Surgery 5 Times Less Compared to SI Joint Fixation with Screws According to New Peer-Reviewed Clinical PublicationJan 20, 2017
ARMO BioSciences Presents New Phase 1b Clinical Data for AM0010 in Advanced Pancreatic Cancer Patients at 2017 Gastrointestinal Cancers SymposiumJan 19, 2017
German Research Foundation (DFG) Purchases ViewRay MRIdian Linac for University Clinic HeidelbergJan 19, 2017
Symbiomix Therapeutics Submits New Drug Application to US FDA for Solosec™ for the Treatment of BVJan 19, 2017
Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing LossJan 18, 2017
Shareholder Circular for proposed consolidation, authority to issue new shares, adoption of new Articles and Notice of Meeting on 8 February 2017Jan 18, 2017
Proposed new Articles for adoption at Meeting on 8 February 2017Jan 18, 2017
ViewRay Raises $26.1 Million in Private PlacementJan 17, 2017
Aeglea BioTherapeutics to Present New Data at 2017 ACMG Annual Clinical Genetics MeetingJan 17, 2017
BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic CancerJan 17, 2017
Adicet Bio Appoints Anne Altmeyer as Chief Business OfficerJan 17, 2017
ObsEva Expands Leadership Team and Board of Directors with Industry VeteransJan 17, 2017
Roka Bioscience Announces Transition of CEO Role from Paul Thomas to Mary DuseauJan 13, 2017
ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm LaborJan 11, 2017
Boehringer Ingelheim and AmoyDx Collaborate to Initiate Blood-based EGFR Mutation Testing in ChinaJan 11, 2017
Intellia Therapeutics Joins Genomics England's Industry ConsortumJan 11, 2017
RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria InfectionsJan 11, 2017
First US Service Members Treated with the Only FDA-Approved Cross-Linking Procedure in the U.S.Jan 11, 2017
Good Start Genetics and Genome Medical Announce Partnership to Provide Genetic Counseling to Couples Undergoing Carrier TestingJan 11, 2017
Affimed Provides Update on NK-Cell Immuno-Oncology PlatformJan 10, 2017
Loxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional SharesJan 10, 2017
Singulex Enters into Collaboration with QIAGEN to Develop Companion DiagnosticsJan 10, 2017
Adimab Provides Annual Update on 2016 Partnerships and MilestonesJan 10, 2017
Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444Jan 9, 2017
Tricida Announces Positive Topline Phase 1/2 Clinical Trial Results for TRC101 in 135 Subjects with Chronic Kidney Disease and Metabolic AcidosisJan 9, 2017
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer ImmunotherapiesJan 9, 2017
Otonomy Provides Corporate and Product Pipeline UpdateJan 9, 2017
Adaptimmune Announces New Senior Vice President of Global Bio-Process and DevelopmentJan 9, 2017
Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target CollaborationJan 9, 2017
Invitae announces new leadership structure to drive global growthJan 9, 2017
Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial GuidanceJan 9, 2017
Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid TumorsJan 9, 2017
SI-BONE, Inc. Announces iFuse Implant System® Warranty Program in Support of Patients, Providers and PayorsJan 9, 2017
argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravisJan 8, 2017
Xenon Pharmaceuticals Outlines Key Milestones for 2017Jan 7, 2017
Alector Announces Closing of Series D Financing – Total Capital Raised in 2015 Exceeds $60MJan 6, 2017
Invitae meets annual volume guidance, projects doubling of volume in 2017, accelerates Genome Network by acquiring scalable patient-centered data companyJan 6, 2017
Invitae acquires patient-centered data company AltaVoice, creating new offerings to advance research and access to care for patients with inherited and rare diseasesJan 6, 2017
Cleave Biosciences Promotes Kanya Rajangam to Chief Medical OfficerJan 5, 2017
10th January 2017: NeRRe Therapeutics CEO, Dr Mary Kerr, presents at the Biotech Showcase, 9-11 January 2017, San Francisco, CA, USAJan 5, 2017
Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development AllianceJan 5, 2017
Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis ExternaJan 5, 2017
Loxo Oncology Prices Follow-On Offering of Common StockJan 5, 2017
Adicet Bio Appoints Anne Altmeyer as Chief Business OfficerJan 5, 2017
Marinus Provides Business Outlook for 2017Jan 5, 2017
NeRRe Therapeutics raises £23 million in oversubscribed Series B financing roundJan 5, 2017
Arvinas Appoints Dr. John Houston as President of Research and Development and Chief Scientific OfficerJan 4, 2017
scPharmaceuticals Announces Closing of $45.6 Million in Series B FinancingJan 4, 2017
Loxo Oncology Announces Proposed Public Offering of Common StockJan 4, 2017
Affimed and MD Anderson Announce Clinical Immuno-Oncology Development CollaborationJan 4, 2017
Pionyr Immunotherapeutics Closes Financing with Focus on Developing Antibody-based Immuno-oncology TherapeuticsJan 3, 2017
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X SyndromeJan 3, 2017
Corvus Pharmaceuticals Names Ian T. Clark, Former Genentech Chief Executive Officer, to Board of DirectorsJan 3, 2017
Graybug Vision Appoints Thomas S. Templeman, PhD, as Chief Operating Officer